Feeds:
Posts
Comments

Archive for the ‘Personalized and Precision Medicine & Genomic Research’ Category

The Incentive for “Imaging based cancer patient’ management”

The Incentive for “Imaging based cancer patient’ management”

Author and Curator: Dror Nir, PhD

Image taken from http://www.breastthermography.com/breast_thermography_mf.htm

It is generally agreed by radiologists and oncologists that in order to provide a comprehensive work-flow that complies with the principles of personalized medicine, future cancer patients’ management will heavily rely on “smart imaging” applications. These could be accompanied by highly sensitive and specific bio-markers, which are expected to be delivered by pharmaceutical companies in the upcoming decade. In the context of this post, smart imaging refers to imaging systems that are enhanced with tissue characterization and computerized image interpretation applications. It is expected that such systems will enable gathering of comprehensive clinical information on cancer tumors, such as location, size and rate of growth.

What is the main incentive for promoting cancer patients’ management based on smart imaging? 

It promises to enable personalized cancer patient management by providing the medical practitioner with a non-invasive and non-destructive tool to detect, stage and follow up cancer tumors in a standardized and reproducible manner. Furthermore, applying smart imaging that provides valuable disease-related information throughout the management pathway of cancer patient will eventually result in reducing the growing burden of health-care costs related to cancer patients’ treatment.

Let’s briefly review the segments that are common to all cancer patients’ pathway: screening, treatment and costs.

 

Screening for cancer: It is well known that one of the important factors in cancer treatment success is the specific disease staging. Often this is dependent on when the patient is diagnosed as a cancer patient. In order to detect cancer as early as possible, i.e. before any symptoms appear, leaders in cancer patients’ management came up with the idea of screening. To date, two screening programs are the most spoken of: the “officially approved and budgeted” breast cancer screening; and the unofficial, but still extremely costly, prostate cancer screening. After 20 years of practice, both are causing serious controversies:

In trend analysis of WHO mortality data base [1], the authors, Autier P, Boniol M, Gavin A and Vatten LJ, argue that breast cancer mortality in neighboring European countries with different levels of screening but similar access to treatment is the same: “The contrast between the time differences in implementation of mammography screening and the similarity in reductions in mortality between the country pairs suggest that screening did not play a direct part in the reductions in breast cancer mortality”.

In prostate cancer mortality at 11 years of follow-up [2],  the authors,Schröder FH et. al. argue regarding prostate cancer patients’ overdiagnosis and overtreatment: “To prevent one death from prostate cancer at 11 years of follow-up, 1055 men would need to be invited for screening and 37 cancers would need to be detected”.

The lobbying campaign (see picture below)  that AdmeTech (http://www.admetech.org/) is conducting in order to raise the USA administration’s awareness and get funding to improve prostate cancer treatment is a tribute to patients’ and practitioners’ frustration.

 

 

 

Treatment: Current state of the art in oncology is characterized by a shift in  the decision-making process from an evidence-based guidelines approach toward personalized medicine. Information gathered from large clinical trials with regard to individual biological cancer characteristics leads to a more comprehensive understanding of cancer.

Quoting from the National cancer institute (http://www.cancer.gov/) website: “Advances accrued over the past decade of cancer research have fundamentally changed the conversations that Americans can have about cancer. Although many still think of a single disease affecting different parts of the body, research tells us through new tools and technologies, massive computing power, and new insights from other fields that cancer is, in fact, a collection of many diseases whose ultimate number, causes, and treatment represent a challenging biomedical puzzle. Yet cancer’s complexity also provides a range of opportunities to confront its many incarnations”.

Personalized medicine, whether it uses cytostatics, hormones, growth inhibitors, monoclonal antibodies, and loco-regional medical devices, proves more efficient, less toxic, less expensive, and creates new opportunities for cancer patients and health care providers, including the medical industry.

To date, at least 50 types of systemic oncological treatments can be offered with much more quality and efficiency through patient selection and treatment outcome prediction.

Figure taken from presentation given by Prof. Jaak Janssens at the INTERVENTIONAL ONCOLOGY SOCIETY meeting held in Brussels in October 2011

For oncologists, recent technological developments in medical imaging-guided tissue acquisition technology (biopsy) create opportunities to provide representative fresh biological materials in a large enough quantity for all kinds of diagnostic tests.

 

Health-care economics: We are living in an era where life expectancy is increasing while national treasuries are over their limits in supporting health care costs. In the USA, of the nation’s 10 most expensive medical conditions, cancer has the highest cost per person. The total cost of treating cancer in the U.S. rose from about $95.5 billion in 2000 to $124.6 billion in 2010, the National Cancer Institute (www.camcer.gov) estimates. The true sum is probably higher as this estimate is based on average costs from 2001-2006, before many expensive treatments came out; quoting from www.usatoday.com : “new drugs often cost $100,000 or more a year. Patients are being put on them sooner in the course of their illness and for a longer time, sometimes for the rest of their lives.”

With such high costs at stake, solutions to reduce the overall cost of cancer patients’ management should be considered. My experience is that introducing smart imaging applications into routine use could contribute to significant savings in the overall cost of cancer patients’ management, by enabling personalized treatment choice and timely monitoring of tumors’ response to treatment.

 

 References

  1. 1.      BMJ. 2011 Jul 28;343:d4411. doi: 10.1136/bmj.d4411
  2. 2.      (N Engl J Med. 2012 Mar 15;366(11):981-90):

Read Full Post »

 

Harvard Group Using Bio-Rad Digital PCR System as Part of NHGRI-Funded Study of Multi-Allelic CNV

 

Reporter: Aviva Lev-Ari, PhD, RN

August 23, 2012

Researchers in the Department of Genetics at the Harvard University Medical School have been awarded $500,000 by the National Institutes of Health for the first year of a four-year project to study multi-allelic copy number variation in the human genome.

As part of the research, the Harvard team is using a Bio-Rad QX100 Droplet Digital PCR system as one of two methods to analyze multi-allelic CNVs in human cohorts. The researchers are also using a computational method that compares available whole-genome sequencing data.

Steven McCarroll, a professor of genetics at Harvard Med and director of genetics at the Stanley Center for Psychiatric Research at the Broad Institute, is principal investigator on the grant, which is being administered by NIH’s National Human Genome Research Institute.

According to a recently published grant abstract, McCarroll and colleagues seek to analyze multi-allelic CNVs, which involve genes and other functional elements for which three or more segregating alleles give rise to a wide range of copy numbers — between two and 10 — per diploid human genome.

These multi-allelic CNVs have been “refractory to widely used analysis methods and are not assessed in the genome-scale molecular or statistical approaches used to study genetically complex phenotypes in humans,” the researchers wrote.

The project builds on research that McCarroll’s group previously conducted on characterizing multi-allelic duplication CNVs of a megabase-long inversion polymorphism in a particular locus of chromosome 17 called 17q21.31, which contains markers previously associated with female fertility, female meiotic recombination, and neurological disease.

As part of that research, published in the August 2012 issue of Nature Genetics, the group analyzed read depth in the locus by applying an algorithm called Genome Structure in Populations, or Genome STRiP, to whole-genome sequencing data from 946 unrelated individuals sampled as part of the 1000 Genomes Project; and used droplet-based digital PCR to analyze 120 parent-offspring trios from HapMap.

http://www.nature.com/ng/journal/v44/n8/full/ng.2334.html

They found that their measurements of integer copy number varied from two to eight, and were 99.1 percent concordant across 234 genotypes in overlapping samples, thus validating both the computational and digital PCR methods.

More specifically, for the digital PCR assay, the group designed a pair of PCR primers and a dual-labeled fluorescence-FRET oligonucleotide probe to both the CNV locus and a two-copy control locus. Then they used a droplet generator from QuantaLife to compartmentalize the PCR reaction into uniform 1-nanoliter emulsion-based droplets containing zero, one, or very few template molecules for each locus; and a droplet reader from QuantaLife to count the number of positive and negative droplets, comparing the droplet counts of the CNV locus to the control locus to determine absolute copy number.

QuantaLife originally developed the droplet-based digital PCR system, but was acquired in October by Bio-Rad, which rebranded the platform as the QX100 Droplet Digital PCR system (PCR Insider, 10/6/2011).

Annette Tumolo, director of the digital biology center at Bio-Rad, told PCR Insider this week that McCarroll has access to two such platforms, one of which is in use at Harvard and was obtained from QuantaLife, and one of which Bio-Rad sold to the Broad Institute.

Tumolo said that Bio-Rad maintains “an active and positive relationship” with the McCarroll lab. “They’ve gotten great results [with the QX100], and were able to rapidly publish the Nature Genetics paper,” Tumolo said.

Under the new NHGRI grant, McCarroll and colleagues plan to “accurately analyze mCNVs in reference populations” using both the computational and digital PCR approach, the researchers wrote in their grant abstract.

“By analyzing these data in a statistical framework that incorporates information about genotypes, allele frequencies, inheritance, and haplotypes, we will place mCNV alleles onto the haplotype maps created by HapMap and 1000 Genomes, and render mCNVs accessible to genotype imputation to the fullest extent possible,” the grant abstract states.

In addition, McCarroll’s group hopes to “deeply characterize mCNVs at 10 biomedically important loci, to understand these polymorphisms at the levels of population genetics, mutational rates and histories, and relationships to clinical phenotypes. Finally, we will pilot inexpensive in silico genome-wide association studies for mCNVs based on statistical imputation into existing GWAS data sets.”

The end goal of the project is to discover relationships between disease risk and gene dosage, which will help reveal the molecular etiology of human disease, the researchers wrote.

Related Stories

Ben Butkus is senior editor of GenomeWeb’s premium content and the editor of PCR Insider. He covers technologies and trends in PCR, qPCR, nucleic acid amplification, and sample prep. E-mail him here or follow his GenomeWeb Twitter account at@PCRInsider.

 

Read Full Post »

Vascular Medicine and Biology: CLASSIFICATION OF FAST ACTING THERAPY FOR PATIENTS AT HIGH RISK FOR MACROVASCULAR EVENTS Macrovascular Disease – Therapeutic Potential of cEPCs

 

Curator and Author: Aviva Lev-Ari, PhD, RN

 

Classification of Fast Acting Therapies for Patients at High Risk for Macrovascular events

Macrovascular Disease – Therapeutic Potential of cEPCs

 

The two leading therapy classes are:

  1. Cell-based Therapies for angiogenesis and myocardial regeneration
  2. Intracoronary Delivery of Autologous Bone Marrow originating cells to restore Ischemic Tissue

The European Meeting on Vascular Medicine and Biology is a biannual international conference. The 3rd European Meeting on Vascular Medicine and Biology, took place in September 2005 and the next conference will be in 2007. All abstract presentations are published in Supplement 2, JOURNAL OF VASCULAR RESEARCH, Volume 42, 2005.

Review of 355 abstracts of posters presented at the conference has identified the following twenty Research Frontiers in Vascular Biology and Vascular Disease.

One abstract is of special interest to the line of research which focus on endogenous augmentation of cEPCs and to reduction of CVD risk by endogenous induction of regression of atherosclerotic plaques. It was selected by being judged to have the highest potential for commercialization and the potential to replace several therapeutic agents with higher efficacy.

P119 IgG1 antibodies against oxLDL epitopes induce regression of advanced atherosclerotic plaques in LDLR-/- APOBEC mice.

A. Schiopu1, B. Jansson2, P.K. Shah3, R. Carlsson3, J. Nilsson1, G. Nordin Fredrikson1Department of Medicine, Malmö University Hospital, Lund University, Malmö, SE; 2 BioInvent International AB, Lund, SE; 3 Atherosclerosis Research Center, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, US.

Objective: The purpose of our study was to assess the effects of recombinant human IgG1 antibodies against specific oxLDL epitopes on advanced atherosclerotic lesions in mice.

Methods: We have tested 2 recombinant human IgG1 antibodies directed to malondialdehyde (MDA)-modified ApoB-100 peptide sequences. Three weekly 1 mg antibody doses were injected intraperitoneally starting at 25 weeks in LDLR-/-Apobec mice, which were then sacrificed at 29 weeks of age. IgG1 antibodies directed against fluorescein isothiocyanate, which do not bind to either native or oxidized LDL, and a

baseline group sacrificed at 25 weeks of age, to asses plaque status before immunization, were used as controls.

Results: Both antibodies induced a significant regression of already present atherosclerotic plaques in the descending aorta as compared to baseline. This effect was not present in the isotype control group. The changes did not depend on alterations in weight, cholesterol or triacylglycerol content in mice plasma.

Conclusions: The present study suggests that antibody treatment has the ability to reduce the extent of already present, advanced atherosclerotic lesions. Passive immunization with antibodies directed against oxLDL epitopes might constitute a future fast acting therapy for patients at high risk for acute cardiovascular events.

Twenty Research Frontiers in Vascular Medicine of Human Endothelium

 

Research Frontiers in Vascular Biology and Vascular Disease 

 

  

International Research Projects

Stem Cell biology Embryonic stem cells in cardiovascularrepairEarly differentiation of human endothelial progenitor cellsVessels transmigration of stem cells depends on activation of the endothelium.

Interaction of embryonal endothelial progenitor cells with platelets

Role of smooth muscle cell progenitors on atherosclerotic plaque development and stability.

 

Ischemia  and Reperfusion Connexin 43 and myocardial ischemia/reperfusioninjuryEndothelialreperfusion injuryA possible role for hypoxia-inducible factor 1• in protection against reperfusion injury

 

Genetic Basis of Vascular Disease Cardiovascular genomics and oxidative stressNox1 mediates basic fibroblast growth factor induced vascular smooth muscle cell migrationReactive oxygen species upregulate NOX4, but not NOX2, in endothelial cells

Induction of prolyl hydroxylase 2 by nitric oxide interferes with the hypoxia induced feedback loop of HIF-1• regulation

Protein disulfide isomerase is a central

regulator of NADPH oxidase activity

 

Inflammation Inflammatory mediatorsofvascularInflammationIsoprostanes inhibit in vitro migration and tube formation of endothelial cells via the thromboxane A2 receptor.

Heme oxygenase-1-dependent and

-independent regulation of angiogenic and inflammatory genes expression in human microvascular endothelial cells

 

Tissue Engineering Engineered heart tissueEndothelial tissue engineeringBlood vessel growth and remodeling in in-vivo tissue engineering

The effects of cyclic strain on the cytoskeleton of vascular smooth muscle cells

 

Atherosclerosis Imaging Experimental In vivo imaging ofatherosclerosisHoming ofCD34+ progenitor cells to sites ofangiogenic tube formation using real-time video microscopy.Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main stems

Cardiovascular Development Controlled by Fluid Shear Stress. A Functionomic Approach.

Dynamics in microvascular alterations in UCP/DTA mice in vivo – from metabolic syndrome to diabetes mellitus type 2

Vascular Cell Signaling TGF-beta in endothelial cell functionandvascular developmentVEGF signaling

 

Atherosclerosis (Clinical / In Vivo) Pathophysiology of cigarette smoking-inducedatherosclerosisThe homeostatic benefits of plaque ruptureEarly coronary atherogenesis as a

consequence of chronic in-vivo proteasome inhibition.

 

Renin-Angiotensin System ACE inhibitorsstimulate endothelialCOX-2expression by aJNK-dependent ACE signalling pathway.A new ACE on the table: ACE2 expression in human atherosclerosis

Role of the ACE gene in renal and vascular complications of diabetes mellitus, experimental study in the mouse.

Bone marrow molecular alterations after

myocardial infarction: impact on endothelial progenitor cells and modulation by ACE inhibition or statin treatment.

Anti-inflammatory properties of Ramiprilat: reduction of monocyte adhesion to angiotensin II-stimulated endothelium is associated with AT1 downregulation.

Activation of phospholipase D by angiotensin II in HUVECS and HMVECS

Pathogenesis of Atherosclerosis Metalloproteinases in vascular pathologywhat we know and what we don’t know.
Stem Cell Therapy Functional assessment of circulatingcellsHuman fetal vascular progenitor cellsaccelerate the healing of ischemic diabetic ulcers

Peri-infarct gene transfer of human tissue kallikrein gene prevents left ventricle dysfunction by stimulating

angiogenesis/arteriogenesis and cardiac stem cell activation and by inhibiting cardiomyocyte apoptosis.

 

Genomics / Proteomics in Vascular Biology Genomic analysis of animal modelsforatherosclerosis.Differential gene expression analysis of tube forming and non-tube forming microvascular endothelial cells in vitro, separated by differences in morphology

Proteomic and metabolomic analysis of

atherosclerotic vessels in ApoE-/- mice

Hypoxic angiogenic transcriptome in human keratinocytes and microvascular endothelial cells: macroarray and real-time PCR analysis.

Gene expression profiling of human red blood cells.

 

Oxidant and Lipid Signaling Lipid modifications in atherogenesis.Epoxyeicosatrienoic acids in vascularHomeostasis

Oxidized phospholipids as modulators of

Inflammation

Chemokines — Cell-Cell Interactions Endothelial cell-to-celljunctionsInterplay ofchemokines and platelets invascular cell recruitment

 

Vascular Development Embryonic vesseldeterminationVascular remodeling: differentiation ofarteries, veins and lymph vessels

 

Vascular Aneurysms and VascularDegradation MMP in aneurysmdevelopmentFurin-likeproproteinconvertases regulate membrane type-1 matrixmetalloproteinase in atherosclerosisNon-viral, electroporation mediated gene

transfer of TIMP-1.ATF, a cell-surface directed MMP inhibitor, suppresses intimal hyperplasia in vein grafts more efficiently than TIMP-1 in vivo.

EMMPRIN regulates MMP activity in

cardiovascular cells. Implications in Acute Myocardial Infarction.

NF-kB promotes monocyte adhesion in vessels exposed to high intraluminal pressure

Diabetes Mellitus and InsulinResistance The endothelial cellglycocalyx indiabetesVasocrine signaling and insulin resistanceEarly arteriogenic defects in a diabetic

ischemic hindlimb model

Diabetes-induced overproduction of reactive oxygen species impairs post-ischemic neovascularization

 

Microparticles / Platelets The significance of membranemicroparticles in vascular pathophysiology andintercellularcommunication.Influences of nuclear receptors on platelet function.

Cellular origin of microparticles in human

atherosclerotic plaques

Apoptotic microparticles derived from

endothelial cells, smooth muscle cells and monocytes induce thrombin generation via different pathways

Smooth Muscle Cells Role of epigenetic mechanisms in control of SMC differentiation in development anddiseaseThe cytoskeletal proteinzyxin is amechanosensitive signaltransducer in vascular smooth muscle cells.Leukotriene-induced migration and

proliferation of vascular smooth muscle cells: implications for atherosclerosis and restenosis

 

Stem Cells Transfer of stem cell-derived endothelial cells retardedneointimal lesions in the injured artery.Stimulation ofreendothelialization viarecruitment of endothelial progenitor cells with selective antibodies against progenitor cell surface markers

Caspase-8 activity is essential for endothelial progenitor cell adherence

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

While a staff nurse at Beth Israel Deaconess Medical Center in Boston, MA in 2008, I provided direct care for Morbid Obese patients, above 400 pounds that were transferred to Farr 9 – the Acute Surgery Unit from the PACU following Bariatric Surgery. The first day after a significant surgical intervention was very tough to the patient and very tough for the nurses, three types of analgesic drugs were used including epidural pumps and PCA. Pain medication diffused in the adipose tissue with just moderate amelioration of pain. Few patients had the operation done 10 years ago and needed a repair. Technology had advanced. More studies are needed to ascertain that in presence of morbid obesity and absence of DM, a Bariatric Surgery is THE Treatment for DM Disease Prevention.

Bariatric Surgery — From Treatment of Disease to Prevention?

Danny O. Jacobs, M.D., M.P.H.

N Engl J Med 2012; 367:764-765  August 23, 2012

Bariatric surgery to treat morbid obesity has improved dramatically over the past 60 years — especially over the past several decades. Today’s methods are far safer than the hazardous intestinal bypass procedures that were introduced in the 1950s. Bariatric-surgery techniques have progressed through various iterations of horizontal and vertical stapling of the stomach with or without banding (e.g., vertical banded gastroplasty) to vertical gastric partitioning or creation of a gastric pouch with proximal bypass into a jejunal loop (i.e., the gastric bypass), which is considered to be a reference standard.

Bariatric Surgery for Morbid Obesity.

Bariatric Surgery for Morbid Obesity.

SOURCE INFORMATION

From the Department of Surgery, Duke University School of Medicine, Durham, NC.

Bariatric Surgery and Prevention of Type 2 Diabetes in Swedish Obese Subjects

Lena M.S. Carlsson, M.D., Ph.D., Markku Peltonen, Ph.D., Sofie Ahlin, M.D., Åsa Anveden, M.D., Claude Bouchard, Ph.D., Björn Carlsson, M.D., Ph.D., Peter Jacobson, M.D., Ph.D., Hans Lönroth, M.D., Ph.D., Cristina Maglio, M.D., Ingmar Näslund, M.D., Ph.D., Carlo Pirazzi, M.D., Stefano Romeo, M.D., Ph.D., Kajsa Sjöholm, Ph.D., Elisabeth Sjöström, M.D., Hans Wedel, Ph.D., Per-Arne Svensson, Ph.D., and Lars Sjöström, M.D., Ph.D.

N Engl J Med 2012; 367:695-704  August 23, 2012

BACKGROUND

Weight loss protects against type 2 diabetes but is hard to maintain with behavioral modification alone. In an analysis of data from a nonrandomized, prospective, controlled study, we examined the effects of bariatric surgery on the prevention of type 2 diabetes.

METHODS

In this analysis, we included 1658 patients who underwent bariatric surgery and 1771 obese matched controls (with matching performed on a group, rather than individual, level). None of the participants had diabetes at baseline. Patients in the bariatric-surgery cohort underwent banding (19%), vertical banded gastroplasty (69%), or gastric bypass (12%); nonrandomized, matched, prospective controls received usual care. Participants were 37 to 60 years of age, and the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) was 34 or more in men and 38 or more in women. This analysis focused on the rate of incident type 2 diabetes, which was a prespecified secondary end point in the main study. At the time of this analysis (January 1, 2012), participants had been followed for up to 15 years. Despite matching, some baseline characteristics differed significantly between the groups; the baseline body weight was higher and risk factors were more pronounced in the bariatric-surgery group than in the control group. At 15 years, 36.2% of the original participants had dropped out of the study, and 30.9% had not yet reached the time for their 15-year follow-up examination.

RESULTS

During the follow-up period, type 2 diabetes developed in 392 participants in the control group and in 110 in the bariatric-surgery group, corresponding to incidence rates of 28.4 cases per 1000 person-years and 6.8 cases per 1000 person-years, respectively (adjusted hazard ratio with bariatric surgery, 0.17; 95% confidence interval, 0.13 to 0.21; P<0.001). The effect of bariatric surgery was influenced by the presence or absence of impaired fasting glucose (P=0.002 for the interaction) but not by BMI (P=0.54). Sensitivity analyses, including end-point imputations, did not change the overall conclusions. The postoperative mortality was 0.2%, and 2.8% of patients who underwent bariatric surgery required reoperation within 90 days owing to complications.

CONCLUSIONS

Bariatric surgery appears to be markedly more efficient than usual care in the prevention of type 2 diabetes in obese persons. (Funded by the Swedish Research Council and others; ClinicalTrials.gov number, NCT01479452.)

Supported by grants from the Swedish Research Council (K2012-55X-22082-01-3, K2010-55X-11285-13, K2008-65x-20753-01-4), the Swedish Foundation for Strategic Research to Sahlgrenska Center for Cardiovascular and Metabolic Research, the Swedish federal government under the LUA/ALF agreement concerning research and education of doctors, the VINNOVA-VINNMER program, and the Wenner-Gren Foundations. The SOS study has previously been supported by grants to one of the authors from Hoffmann–La Roche, AstraZeneca, Cederroth, Sanofi-Aventis, and Johnson & Johnson.

Dr. Lena Carlsson reports receiving consulting fees from AstraZeneca and owning stock in Sahltech; Dr. Bouchard, receiving consulting fees from New York Obesity Nutrition Research Center, Pathway Genomics, Weight Watchers, and Nike, payment for manuscript preparation from Elsevier and Wiley-Blackwell, royalties from Human Kinetics and Informa Healthcare, honoraria from NaturALPHA, and reimbursement for travel expenses from European College of Sports Sciences, Nordic Physiotherapy, Wingate Congress, and Euro Sci Open Forum; Dr. Björn Carlsson, being employed by and owning stock in AstraZeneca; Dr. Sjöholm, owning stock in Pfizer; Dr. Wedel, receiving consulting fees from AstraZeneca, Pfizer, Roche, and Novartis; and Dr. Lars Sjöström, serving as a member of the board of Lenimen, receiving lecture fees from AstraZeneca and Johnson & Johnson, and providing an expert statement on drug effects and weight-loss effects on obesity for AstraZeneca. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Drs. Carlsson and Peltonen contributed equally to this article.

We thank the staff members at 480 primary health care centers and 25 surgical departments in Sweden that participated in the study; and Gerd Bergmark, Christina Torefalk and Lisbeth Eriksson for administrative support.

SOURCE INFORMATION

From the Institutes of Medicine (L.M.S.C., M.P., S.A., Å.A., B.C., P.J., C.M., C.P., S.R., K.S., E.S., P.-A.S., L.S.) and Surgery (H.L.), Sahlgrenska Academy at the University of Gothenburg, and the Nordic School of Public Health (H.W.), Gothenburg, and the Department of Surgery, University Hospital, Örebro (I.N.) — all in Sweden; the Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki (M.P.); and Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge (C.B.).

Address reprint requests to Dr. Lars Sjöström at the SOS Secretariat, Vita Stråket 15, Sahlgrenska University Hospital, S-413 45 Gothenburg, Sweden, or at lars.v.sjostrom@medfak.gu.se.

N Engl J Med 2012; 367:695-704

Read Full Post »

 

Reporter: Aviva Lev-Ari, PhD, RN

Gordon H. Sun, M.D., Jeffrey D. Steinberg, Ph.D., and Reshma Jagsi, M.D., D.Phil.

N Engl J Med 2012; 367:687-690   August 23, 2012

Since the founding of the National Institutes of Health (NIH) and the National Science Foundation (NSF) more than six decades ago, the United States has maintained a preeminent position as a government sponsor of medical research. That primacy is being tested, however, by potent economic challenges. The NIH’s proposed budget for fiscal year 2013 would freeze baseline funding at 2012 levels, continuing a decade-long failure to keep pace with the rising costs of conducting medical research. Across-the-board cuts mandated by the Budget Control Act (BCA) of 2011 will also affect medical research, with the NIH, NSF, and other federal research sponsors sustaining budgetary reductions of about 8% next year.

Cuts to government-funded research will have adverse long-term effects on the health care system and the economy and may irreversibly compromise the work of laboratories long accustomed to receiving stable federal support. Moreover, many medical researchers could transfer their knowledge and resources abroad. In fact, five emerging Asian economic or technological powers — China, India, South Korea, Taiwan, and Singapore — already have medical research policies in place that are filling the void being created by ever more restrictive U.S. funding.

Several U.S.-based economists have justified increasing research budgets on the premise that medical discoveries have intrinsically high economic value. For example, Murphy and Topel have suggested that eliminating deaths related to heart disease had an estimated worth of $48 trillion, and a 1% reduction in cancer-related mortality could save $500 billion.1 Beyond these ambitious goals, however, are more practical arguments favoring support for medical research.

Local and regional economic benefits are one example. A June 2008 analysis by Families USA showed that during the NIH’s fiscal year 2007, nearly $23 billion in grants and contracts supported more than 350,000 jobs, with each dollar generating more than twice as much in direct state economic output in the form of goods and services. The NIH reported that almost 1 million Americans worked in for-profit medical businesses in 2008, earning $84 billion and generating $90 billion in goods and services, reinforcing the importance of preserving the U.S. position as a “knowledge hub” for medical research.2 Nevertheless, BCA cuts next year could result in at least 2500 fewer NIH grants, 33,000 fewer jobs, and a $4.5 billion loss in economic activity.3 Since the NIH’s budget represents less than 1% of overall federal spending, policymakers must reconsider whether shaving 8% from NIH outlays will have a noticeable positive effect on the national deficit or economy.

Fallout from funding cuts could include shifts in the U.S. medical research workforce. In 2000, the National Research Council noted both an overall shortage of medical researchers and inadequate funding for scientists working in the United States, which coincided with a decline in the number of funded NIH grant applications from 31% in fiscal year 2002 to 19% in 2010. This change is particularly critical for postdoctoral researchers, who represent the majority of the U.S. biomedical science workforce. According to the NSF, nearly half the 14,601 new postdoctoral-level researchers who were trained in the United States in 2009 were not U.S. citizens or permanent residents. If U.S. institutions are willing to devote money, training, and infrastructure to support talented, committed researchers, it would be an illogical waste of resources and poor long-term strategy to reduce federal grant mechanisms and wipe out potential job opportunities. Indeed, declining financial support may well encourage medical researchers to seek employment elsewhere.

As compared with the United States, China, India, South Korea, Taiwan, and Singapore have taken a sharply different view of medical research and have developed policies that foster medical research as an engine for economic growth and intellectual innovation (see tableMajor Government Agencies in Asia and Their Budgets for Medical Research.). Their national budgets are heavily based on scientific research and development, and funding is increasing, with budgetary targets ranging from 2 to 5% of their gross domestic products (GDPs). India’s funding goal for medical research alone is 2% of its GDP.

Increased funding for research infrastructure attracts scientists and organizations interested in high-quality research, including clinical trials. During the past two decades, increasing numbers of clinical trials have moved overseas, where benefits can include decreased costs of doing business, fewer administrative regulations, and greater enrichment of international relationships among researchers. The average annual rate of growth in clinical trials has been highest in China — 47% — while the number conducted in the United States has decreased by an average of 6.5% annually.4 In addition, the increased attention paid to Asia by private firms and other nongovernmental organizations has spurred rapid policy-level responses to concerns about the lack of informed consent, transparency, and other ethical issues, thus further strengthening the appeal of conducting research in the region.

Asian policies reflect a recognition of the extrinsic economic benefits of medical research. China and India have advocated for more government-funded medical research to improve health-related outcomes. China has espoused increased spending as part of achieving xiaokang, a Confucian term meaning a moderately prosperous society. In 2007, India inaugurated its Department of Health Research, which coordinates biomedical science and health-services research programs and translates their findings to address public health concerns. Since the signing of the Korean War Armistice Agreement in 1953, South Korea has leaned heavily on government-funded research to reduce poverty, allowing the country to gradually acquire advanced technologies and expertise. Medical research is part of at least two core technology areas in South Korea’s “577 Initiative”: medical technologies, such as neuroimaging, to address the needs of an aging population and research on issues pertaining to national safety and public health, such as infectious-disease preparedness and food safety.

National research and development programs have been a fundamental component of Taiwan’s economic policy for at least five decades. In 2005, the country began developing “intelligent medical care” — similar to earlier U.S. initiatives — which integrates medical information technology with quality-improvement measures. In Singapore, medical research and economic oversight are administratively linked. For example, the Biomedical Sciences Group of the Economic Development Board supports researchers financially and designs strategies that enhance Singapore’s status as a knowledge center, and the private firm Bio*One Capital invests directly in promising medical technologies.

The diverse strategies outlined above allow Asian countries to systematically recruit medical researchers from both home and abroad. China is particularly proactive in enticing Chinese-born, U.S.-educated researchers to return to their native country by offering generous financial and material incentives under its Knowledge Innovation Program. As the vice president of the Chinese Academy of Sciences stated more than a decade ago, modern “research and development is actually a war for more talented people.”5 In 2000, Singapore jump-started its Biomedical Sciences Initiative to attract medical researchers worldwide with a direct $2 billion investment, as well as with tax incentives for internal biotechnology start-ups and global pharmaceutical firms. In Singapore and India, English is the primary language for scientific communications, which alleviates concerns about language barriers.

For two decades, emerging Asian countries have been designing long-term strategies to reap the benefits of medical research. Meanwhile, the United States is relying on short-term solutions to support its medical research infrastructure, such as those offered by the Patient Protection and Affordable Care Act and the American Recovery and Reinvestment Act. Decreased investment in U.S. medical research could lead to long-term economic damage for the United States and the loss of its stature as a global leader in the field. Powerful incentives that can retain an elite biomedical-research workforce are necessary to strengthen the U.S. health care system and economy.

The views expressed in this article are those of the authors and do not necessarily reflect those of the Robert Wood Johnson Foundation, the Department of Veterans Affairs, or the Agency for Science, Technology, and Research.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

SOURCE INFORMATION

From the Robert Wood Johnson Foundation Clinical Scholars Program (G.H.S., R.J.), the Department of Otolaryngology (G.H.S.), and the Department of Radiation Oncology (R.J.), University of Michigan, and the Health Services Research and Development Service, VA Ann Arbor Healthcare System (G.H.S.) — both in Ann Arbor, MI; and the Singapore Bioimaging Consortium, Agency for Science, Technology, and Research, Singapore (J.D.S.).

http://www.nejm.org/doi/full/10.1056/NEJMp1206643?query=TOC

 

 

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

 
 
 
Fluidigm Corporation (NASDAQ: FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips, assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets four microfluidic systems, including nine different commercial chips, to leading academic institutions, diagnostic laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. Fluidigm products are marketed for research purposes only (not for diagnostic use).
Fluidigm Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $60 million Public Offering of Common Stock

SOUTH SAN FRANCISCO, CALIFORNIA – August 21, 2012 – Fluidigm Corporation (NASDAQ: FLDM), a supplier of microfluidic systems for growth markets in the life science and agricultural biotechnology industries, today announced that it has closed the previously announced underwritten public offering of 4,209,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of approximately $60 million. The shares include 549,000 shares of common stock sold pursuant to the over-allotment option granted by Fluidigm to the underwriters, which option was exercised in full. The net proceeds from the sale of the shares, after deducting the underwriters’ discounts and commissions and other estimated offering expenses payable by Fluidigm, will be approximately $56.1 million.
Fluidigm currently plans to use the net proceeds from this offering for research and development, commercialization of its products, working capital and other general corporate purposes.
Piper Jaffray & Co. and Cowen and Company, LLC acted as the joint book-running managers for the offering.  Leerink Swann LLC, Oppenheimer & Co. Inc. and Cantor Fitzgerald & Co. acted as the co-managers for the offering.

A shelf registration statement (File No. 333-180550) relating to these securities was filed on April 4, 2012, as amended on May 7, 2012, and declared effective by the Securities and Exchange Commission on May 10, 2012.  A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC on August 16, 2012.  Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com, or from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140). An electronic copy of the prospectus supplement and accompanying prospectus relating to the offering is available on the website of the Securities and Exchange Commission at http://www.sec.gov/.
This press release does not constitute an offer to sell or the solicitation of offers to buy any securities of Fluidigm, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

In order to provide Fluidigm’s investors with an understanding of our current intentions and future prospects, this release may contain statements that are forward-looking.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include our expectations regarding the offering and the use of proceeds from such offering.
Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including market risk and the risks we identify in reports filed with the SEC.
Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the SEC. Fluidigm does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

 
 

The C1™ Single-Cell Auto Prep System is a new approach to single-cell gene expression.

 
For the first time, extract, reverse transcribe, preamplify, and ultimately detect and analyze cell activity using just one technology:

 

  • Resolves individual cells 
  • Easy and intuitive 
  • Cell input to data in less than a day
  • Reduced technical noise for reliable results
  • qPCR profiling of gene expression
 
 
 
 
 

Applications

 

Learn about the advantages of Integrated Fluidic Circuits (IFCs) for your specific application.

Gene Expression
High throughput • Low cost • Compatibility with existing
reagents
a2.pngSingle-Cell Gene Expression
High sample throughput • More results faster • Assay
flexibility
   
a6.pngSNP Genotyping
Higher sample throughput • Outstanding data quality •
Dramatically lower costs
a5.pngTargeted Resequencing
Target enrichment • Sample barcoding for multiplexed
sequencing • Sequencing
library preparation using amplicon tagging
   
a1.pngSample Quantitation
Ability to amplify individual
molecules • Accurately and
reproducibly determine
library concentrations
a4.pngCopy Number Variation
High-resolution CNV studies using digital PCR •
Simple, fast, and reliable workflow • Standard
assays and reagents
 

Research Publications Featuring Fluidigm Products

 

Select from the Following Categories:

Gene Expression

Single-Cell Gene Expression

SNP Genotyping

Targeted Resequencing

Number Variation/Digital Quantification

Other

Gene Expression

 

Single-Cell Gene Expression

 

SNP Genotyping

 

Targeted Resequencing

 

Copy Number Variation/Digital Quantification/Digital PCR

Protein Crystallization

 

Products

Fluidigm develops and distributes life science systems based on our proprietary Integrated Fluidic Circuits (IFCs).  We currently offer the following complete systems and products:

b5.pngBioMark™ HD System
Reproducible results down to
a single cell • Fast PCR enabled •
Collect more data points per
day • Multiple reagents with different sample configurations
Granicus_Right_315.jpgC1™ System
Single-cell precision • Easy to use • Fast—cell input-to-data • All in one—comprehensive • Flexible—expandable
   
b3.pngAccess Array™ System
Target enrichment • Sample
barcoding for multiplexed
sequencing • Sequencing library prep using amplicon tagging
b4.pngEP1™ System
Accelerated workflow • Outstanding data Quality • Efficient high sample throughput SNP Genotyping
   
b2.pngDeltagene™ Assays
High quality—sensitivity and linearity
similar to probe-based assays •
MIQE* compliant—assay primer
sequences provided • Cost savings
—low startup and running costs
b6.pngChips & Kits
192.24 – 192 samples x 24
assays  • 48.48 – 48 samples x 48 assays • 96.96 – 96 samples x 96 assays
   
AA_TS_Primers_Image.jpgTarget-Specific Primers
Custom-designed primer sets •
multiplex capability allows up to 480 amplicons per sample • Amplicon tagging bypasses traditional library preparation
b1.pngSNPtype™ Assays 
Low start-up and running costs • Locus-specific primer sequences provided • Change targets on demand
#
topazproduct.pngOther Products

 

Read Full Post »

 

Reporter: Aviva Lev-Ari, PhD, RN

Will ‘gamifying’ drug R&D win more than Facebook fans for Boehringer?

By Tracy Staton, FiercePharma, August 22, 2012

Lots of computer games enlist players in quests to save the world. But how many would-be saviors are developing drugs? We can’t think of any–until now. Boehringer Ingelheim is on the verge of launching Syrum, a Facebook game of test tubes and titrations, not crossbows and assault rifles.

 “The health of the world is in your hands,” Boehringer’s director of digital, John Pugh, tells PSRK, in what could be a voice-over for a YouTube promo video for the game. “And you’re the only one who can save it.”

 Players have to solve a problem–e.g., a pandemic–via drug development, all the way from early discovery through clinical trials and launch. They can enlist help from Facebook friends, and advance in the game by checking into locations via the social network’s mobile app. “It wasn’t built with a view to being an educational platform,” Pugh says. “It’s very much a game which is meant to be engaging and entertaining … In the same way that Farmville doesn’t just appeal to people who like farms, Syrum isn’t just for people who like the pharmaceutical industry.”

But it was education that drew Pugh and his team into the project; as he points out for PSFK, the industry does a lot of it, whether that’s “educating” doctors about products, or teaching patients how to take their meds properly. Just because the game isn’t designed as an educational platform doesn’t mean it can’t educate, in a stealthy, backhanded way.

Syrum has been in development for two years. On Sept. 13, Boehringer will unveil a beta version at a London conference, aiming to get feedback from players for future iterations. “[T]he game will grow and evolve as more people play it,” Pugh says.

He also says Syrum is a “very unique offering from a highly regulated industry.” True. Whether it will remain unique depends, in part, on how Syrum actually fares. Will it attract a following? And if it does, will gamification of drug development actually benefit Boehringer’s business? Image? Relations with patients? Pharma’s social media advocates (and skeptics) will be watching.

John Pugh, Director of Digital for Boehringer Ingelheim, talks about driving innovation in his large organization with the forthcoming game Syrum – which he will launch at PSFK CONFERENCE LONDON on September 13.
 
 
 
 
By Tim Ryan on August 21, 2012.
  • John Pugh is the Director of Digital for Boehringer Ingelheim GmbH – a group of pharmaceutical companies that specialize in research and development for prescription medicine products. He spoke to PSFK recently about driving innovation in a large organization with his forthcoming game Syrum – which he will launch at PSFK CONFERENCE LONDON on September 13.

Your company has a new game, Syrum. What is it – and why is a pharmaceutical company like Boehringer Ingelheim involved in it?

What really sparked my interest in the potential of gaming is that a lot of what we do in pharma is around educating and teaching people; whether that’s teaching doctors about specific products, educating the general public and patients about diseases and healthy ways to live, or teaching people how to take their medication.

Gaming seems to be a useful way and effective way for us to do that. I basically began the journey to try and work out what I could do in gaming that wasn’t an arcade or platform based game — but was something a bit more immersive.

Syrum has been in development for at least two years. At the beginning, we called in lots of experts from different industries, different locations in countries, and with different skill sets. We had various leaders, from specialized futurologists to branding experts, from pharma people to gaming people, and even young entrepreneurs who’d made a million dollars by the age of 17.

We really worked together to create a vision of the future, and one of the strong things that came through was the influence of gaming and gamification.

After two years of hard work, the result is that we are about to launch Syrum, the pharmaceutical industry’s first social game.

syrum-boehringer-ingelheim

Can you tell us a little more about the gameplay in Syrum?

Syrum is a social game. The health of the world is in your hands, and you’re the only one who can save it. In each chapter, you have to solve a particular problem, which could be a disease or a pandemic that is sweeping the world. The player’s goal is to discover cures, create a stable drug, and then create a clinical trial so that you can launch the drug and cure the disease.

It’s a social game, because you can collaborate with friends or other people, and you can give them gifts, even headhunt their staff. As the game progresses, it gets more and more complicated.

syrum-boehringer-ingelheim-game

What do you think people will get out of it?

First, it’s a fun game. It wasn’t built with a view to being an educational platform or anything like that. It’s very much a game which is meant to be engaging and entertaining to play. In the same way that Farmville doesn’t just appeal to people who like farms, Syrum isn’t just for people who like the pharmaceutical industry. It’s for anyone to play.

It’s built on Facebook because that’s the world’s biggest gaming platform. What we really wanted to do was try to use a lot of the features of Facebook. For example we leverage Facebook Places, a service where people can check into locations. It’s really bridging that offline/online world. Places helps players market the products they make. Wherever the players check in through the Facebook mobile app, that data gets integrated into the game and you get rewarded accordingly.

syrum-boehringer-ingelheim-game

When will it be available?

September 13. We are taking a Silicon Valley approach, where we know we have got a really good game that’s stable but we’ll launch a beta version. We really want to make it so that we get lots of feedback from the people who are playing.

We’re offering rewards and prizes for people to give feedback so that we can really create the duration of the game, and develop it, and have more of a crowdsourced collaborative effort to develop the future stages of it, so the game will grow and evolve, as more people play it. This is a very unique offering from a highly regulated industry.

Can we finish by understanding your role within the organization – and how you drive change.

My job is anything which is connected to digital, so that includes apps, mobile, websites, gaming, crowdsourcing, and so forth. Our goal is to find applications for all of that. I bring to this company new ideas and I inspire them, educate them, cajole them, prod them to try new things, particularly in digital. I want BI to stretch out beyond the traditional marketing activities because in pharmaceuticals, and particularly at Boehringer, we’re still very traditional in what we do.

Thanks John!

Come see John talk about the launch of Syrum at PSFK CONFERENCE LONDON.

Syrum / @johnpugh / Boehringer Ingelheim

Click the banner below to purchase tickets and find additional information about this year’s event.

 

via PSFK: http://www.psfk.com/2012/08/pharma-social-game-psfk-london.html#ixzz24IgR5ZEm

http://www.psfk.com/2012/08/pharma-social-game-psfk-london.html

How Sanofi Is Writing The Social Media Rules For Big Pharma Without Running Afoul Of The FDA

BY BEN PAYNTER

 | 

AUGUST 20, 2012

After a Facebook PR meltdown two years ago, Sanofi has emerged as a social media leader with a robust community for diabetics. Here’s how they are writing #TheRules while the FDA catches up.

About This Series

#therules

Follow Fast Company’s roadmap to social media: surefire rules, data, and expert wisdom guaranteed to show why this market is completely unpredictable.READ MORE

The biggest challenge to treating patients with diabetes isn’t doling out medications, it’s making sure that people control their habits. Poor diet and lack of exercise generally create complications with the disease. To combat the problems, researchers in the diabetes division of Sanofi US took an unusual step for Big Pharma: they went social, jumping into online networking with a Facebook page, Twitter presence, and eventually three different engagement platforms.

“Treatment is an important aspect to blood sugar management, but it isn’t the only aspect,” says Laura Kolodjeski, Sanofi’s diabetes community manager, who has become the virtual face of the company. “There is a huge community of people already that live with diabetes and are connecting and sharing [online] to improve each other’s experience with the disease.”

 

Laura Kolodjeski

 

Sanofi now helps direct and police those interactions online. The company won’t release total visitor numbers, but it has about 4,000 followers on Facebook and another 4,000 on Twitter, all of whom are sharing links to broader content. And for better or worse that community is going to grow: About 8 percent of Americans or roughly 26 million people have diabetes, and the Centers for Disease Control predicts that as many as one third of us could have the disease by 2050.

But the social frontier is potentially prickly for Sanofi because the FDA has not yet written the rules about how pharmaceuticals are allowed to engage with potential customers and patients. The only guidelines came out in a December 2011 advisory statement declaring that while allowing virtual comments about things like off-label uses isn’t technically illegal, it’s shady territory; basically, pontificate at your own risk. “We are working on the area and it’s something we feel is important but we don’t have a specific timeline right now,” says Ernest Voyard, senior regulatory council at the FDA’s Office of Prescription Drug Promotion.

For Sanofi, drawing up their own social media strategy is also a defensive move: In 2010, the company’s cancer division suffered a PR nightmare after a patient, who claimed to have experienced permanent hair loss from one of their treatment drugs, posted complaints and photos on that group’s unmonitored Facebook page. John Mack, the editor of Pharma Marketing News, which tracks shifts in the pharmaceutical industry, says such hits are common anytime you try to pioneer a new space. “They’ve had some rough times, but they are learning a lot,” he adds.

Mack considers Sanofi a leader in the category, especially compared with the offerings from other companies. Diabetes juggernaut Novo Nordisk sponsors IndyCar driver Charlie Kimball to tweet @racewithinsulin, including when he injects with their products. And Pfizer’s ThinkScienceNow blog about developments and advances in research is wonky but not exactly customer friendly.

Sanofi has created a template they hope will eventually be deemed both acceptable to the FDA and cool for customers. The lessons they’ve learned in the last two years is a valuable addition to The Social Media Roadmap from our current issue.

Be Transparent

When she took over as social media director, one of the first things Kolodjeski did was post a bio with a photo of herself online at DiscussDiabetes to show who was moderating. She also disclosed that she wasn’t diabetic. Why? To build trust, the kind community members might not have for a faceless company run by mostly non-diabetics. The message: “If Laura is going to work every day to solve [issues] on our behalf, then others must be doing the same,” Kolodjeski says.

Rather than just explain the rules of their forums in a jargon-y “terms of use” agreement Kolodjeski also tapped Mark Gaydos, head of the company’s U.S. regulatory affairs for marketed products division, to do a Q&A about how the sites would function. For instance, anytime someone on the site mentions a product, they are technically promoting it, so there needs to be fair balance of potential benefits and risks explained alongside that per FDA guidelines. That means many posts get quarantined internally before posting, so the company can add additional links or annotations to more information. Sanofi only wants to allow discussion of FDA-approved uses for products–any mention of possible side-benefits or bonuses from tweaking the usual dose regimen is prohibited. To make sure everything meets these requirements, there is often a delay–sometimes up to 24 hours–between when users make comments and those comments become publicly visible.

To explain their business interest, Kolodjeski also interviewed Dennis Urbaniak, the head of the company’s U.S. diabetes business unit to explain what he calls the “360-degree partner” principle–an effort to inspire others to talk more and tap into that as a focus group for new ideas.

Let Users Shape Expansion

Sanofi launched their diabetes Facebook and Twitter handles in September 2010 mainly to offer news updates about the company and its offerings. On Facebook, any clinical questions were directed to a separate tab and often answered privately. On Twitter, medical concerns were covered via direct message. What was missing was a way to collect various poster’s lifestyle tips and inspirational messages all in one place. In January 2011, the company launched DiscussDiabetes to address that. They also run their own stories about successes, including highlights from A1C Champions, another company sponsored group of diabetics who have maintain the best or “A1C” target range of blood sugar levels.

By March of this year, the company took a look at the discussions that were being generated and realized that terms like A1C weren’t actually as universally understood as they once thought. To speed that learning curve, they launched Diabetepedia, which provides both simple definitions and links to other sites showing how terms are actually used in other online conversations.

The final step: After noticing how activity at Diabetepedia was spiking, Sanofi launched another site collecting lots of the content they were already linking to all in one place. The DX, which launched at the end of May, hosts daily dispatches by both Kolodjeski and stable of already popular bloggers (none of whom are paid directly) that include everything from a diabetes related comic strip to mommy blogs for parents with diabetic kids. “We really allowed the community to help identify what might be useful to them and where they might go next,” Kolodjeski says.

Give Users Even More Control

The medical glossary at Diabetepedia doesn’t just provide standard definitions to complex terminology, users are encouraged to submit their own entries, creating a sort of slang dictionary that makes complicated stuff more relatable to newcomers. For instance, glucoaster: that’s shorthand for “a rollercoaster of blood glucose levels, with blood sugar lows followed by blood sugar highs.” User contributions have helped the database grow by 30 percent to include more than 150 terms, all of which make it easier to users themselves to better convey thoughts in future postings.

The company also considers each media outpost an exclusive “channel,” which means there is lots of cross-posting of content from different platforms to make sure users who only tune into one place are being best served. “We certainly have people that overlap but for the most part people have selected which channel they feel represented by and communicate through,” Kolodjeski says. But at each stop, the company still tries to crowdsource bigger ideas.

This year, they asked users to help set priorities for the company’s annual Data Design Diabetes Innovation Challenge, which asks individuals, businesses and non-profits to create new initiatives for using big data to help others struggling with the disease. To help brainstorm for that, Sanofi’s social media troop was given the chance to visit a competition homepage and answer questions about what aspects of life with the disease might be consistently overlooked or ignored. Their answers were used to shape a final guideline for contestants that solutions must address the overall wellness and family life of patients, not just symptom mediation. The winner: a program created by the n4a Diabetes Care Center that matches people with certain cost or risk profiles directly to the services they might need to slow the progression or expense of the disease. Mood problems can be addressed by better disease management, hopefully cutting into the 18 percent of all diabetics who require hospitalization each year.

After realizing just how open users are to sharing and connecting, Sanofi also launched their own new product, the iBGStar, a personal blood glucose monitor that plugs directly into an iPhone or iPod Touch with an app that saves data and maps correlations between blood sugar levels and meal times, carb and sugar intake, and physical activity. Users can share results with their family or email them to health care providers. But the product, which hit the market in May 2012, wasn’t just inspired by early community actions; ensuing reviews and comments in their own forums will help refine future updates. “It’s a big hit with the online community,” Kolodjeski says. “It’s also given us a great opportunity to prove back to them that if we hear someone comment about something, we have the ability to engage in a public manner.”

Correction: An earlier version of this article said that iBGStar came on the market in 2011, it was released in May 2012.

http://www.fastcompany.com/3000457/how-sanofi-writing-social-media-rules-big-pharma-without-running-afoul-fda

Lilly to develop company-wide social media strategy

11 Jul 2012

 
Nearly two years after launching its first major foray into the world of social media in the shape of its LillyPad corporate blog, Eli Lilly is developing a company-wide social media strategy.

Lilly has so far had strict rules about who can use social media on behalf of the company, authorising just a handful of people in corporate communications and government affairs, but now wants to empower other departments to do so.

“There are a lot of parts of the company that are getting interested in social media so I’m working on a strategy that will keep these aligned with one another,” Lilly’s director of corporate communications Greg Kueterman told SMI’s Social Media in the Pharmaceutical Industry conference on Monday.

“We don’t want to have eight different social media platforms that all look and sound very different from one another. So we’re going to try and do something where they all have their own identity but are still consistent within the company.”

Kueterman acknowledged LillyPad, launched September 2010, and the company’s Campaign For Modern Medicines, a US health policy initiative Lilly founded last year that uses Twitter, Facebook and YouTube, were set up “before we had a full blown strategy”.

“But sometimes that is important,” he said. “Because you have to know what you have, before you can make it even bigger.”

The company’s Clinical Open Innovation team, a group working to improve the drug development process, also began using social media earlier this year, with a blog and Twitter account.

The next stage for Lilly will be to continue its expansion of LillyPad (as previewed herein March), following the launch in May of a Canadian version of the corporate blog.

“We’ve started to go global with LillyPad and we’re working with a number of our affiliates to do this. Lilly Canada has been the first one out of the box to do that and they’re off to a nice start,” Kueterman said.

Discussions are underway with the company’s European affiliates in the UK and Belgium along with its operations in Mexico. “Hopefully some of those are going to be launching this year, although we don’t have firm dates yet,” Kueterman said.

“We’re excited that this is a programme that’s going to start picking up momentum. Looking ahead there are still things that we can do much better. I’m never really satisfied with the way things are going with LillyPad – I’m happy, because I think we’re doing things the right way, but I also believe that we can be even more proactive than we are.”

• Links to Lilly’s social media presences can be found in the Pharma Social Media Directory‘s blogsTwitterFacebook and YouTube sections 

http://www.pmlive.com/digital_intelligence_blog/archive/2012/jul_2012/lilly_to_develop_company-wide_social_media_strategy

What Else Can We (Really) Do?

by Greg Kueterman 07/10/12 


On Monday, I had the pleasure of presenting Lilly’s social media history and strategy at a conference in London. The history part was easy: LillyPad — our first major platform — has been around for 22 months. We’re not experiencing the Terrible Twos just yet, but we’ve still got plenty to learn.

The London audience — consisting of European and U.S. communicators and marketing experts at the Social Media for Pharmaceutical Industry conference. — warmly embraced our strategy of addressing issues such as public policy and medical innovation. And the reception was not unusual. Over the last two years, we’ve talked LillyPad in live settings from London to New York to Indianapolis to San Francisco — and our peers typically offer two thumbs up for the good work.

For that, we are grateful. But it’s a good reminder about a couple questions we need to ask more often:

What else can we be doing? What else should we be doing?

As our loyal readers, you know what we offer — and you know what you need to become more informed. We would love to hear more from you: the good, the bad, and the ugly. We’re always looking to enhance LillyPad, and we’ve taken a lot of steps in recent months to do so (more video, more guest blogs, and — we think — clearer, more conversational writing). And while we will remain a non-product communications vehicle, we’re open to any and all ideas that make your LillyPad experience even better.

From London (where I’ve seen more rain in three days than my backyard has seen in two months) thanks for reading!

http://lillypad.lilly.com/entry.php?id=1736

 

 

Read Full Post »

Reported by: Dr. V.S. Karra, Ph.D

Transcription is a cellular process by which genetic information from DNA is copied to messenger RNA for protein production. But anticancer drugs and environmental chemicals can sometimes interrupt this flow of genetic information by causing modifications in DNA.

Chemists at the University of California, Riverside have now developed a test in the lab to examine how such DNA modifications lead to aberrant transcription and ultimately a disruption in protein synthesis.

The chemists report that the method, called “competitive transcription and adduct bypass” or CTAB, can help explain how DNA damage arising from anticancer drugs and environmental chemicals leads to cancer development.

“Aberrant transcription induced by DNA modifications has been proposed as one of the principal inducers of cancer and many other human diseases,” said Yinsheng Wang, a professor of chemistry, whose lab led the research. “CTAB can help us quantitatively determine how a DNA modification diminishes the rate and fidelity of transcription in cells. These are useful to know because they affect how accurately protein is synthesized. In other words, CTAB allows us to assess how DNA damage ultimately impedes protein synthesis, how it induces mutant proteins.”

Study results appeared online in Nature Chemical Biology on Aug. 19.

Wang explained that the CTAB method can be used also to examine various proteins involved in the repair of DNA. One of his research group’s goals is to understand how DNA damage is repaired—knowledge that could result in the development of new and more effective drugs for cancer treatment.

“This, however, will take more years of research,” Wang cautioned.

His lab has a long-standing interest in understanding the biological and human health consequences of DNA damage. The current research was supported by the National Cancer Institute, the National Institute of Environmental Health Sciences and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

Wang was joined in the research by UC Riverside’s Changjun You (a postdoctoral scholar and the research paper’s first author), Xiaoxia Dai, Bifeng Yuan, Jin Wang and Jianshuang Wang; Philip J. Brooks of the National Institute on Alcohol Abuse and Alcoholism, Md.; and Laura J. Niedernhofer of the University of Pittsburgh School of Medicine, Penn.

Next, the researchers plan to use CTAB to investigate how other types of DNA modifications compromise transcription and how they are repaired in human cells.

A quantitative assay for assessing the effects of DNA lesions on transcription

Source:

http://www.rdmag.com

University of California, Riverside

 

 

 

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

 

Synthetic Biology

This collection aims to highlight PLOS ONE‘s role in the emerging interdisciplinary field of synthetic biology. The collection has its roots in PLOS ONE‘s very first issue, which included two publications from the field and since then, the number of synthetic biology articles published by the journal has grown steadily. As the field continues to develop, this collection will be updated to include new publications, thereby tracking the evolution of this dynamic research area.

Synthetic biology occurs at the intersection of a number of traditional disciplines, including biology, chemistry, and engineering. It aims to create biological systems that can be programmed to do useful things such as producing drugs and biofuel. The interdisciplinary nature of synthetic biology can make it difficult to publish in traditional journals. PLOS ONE‘s broad scope, however, allows for the publication of work crossing many traditional research boundaries, making it an ideal venue for many different types of synthetic biology publications. In addition, the journal’s focus on rigorous peer review without considering impact has made it possible to publish a body of articles that truly reflects the multifaceted nature of this research area.

One overarching theme of synthetic biology is standardization, which can only be achieved through concerted community effort. To this end, each article published in PLOS ONE can be the start of a lively conversation. The ability to comment on articles provides the community with a means to engage in a dialogue focused on specific articles, and the “Share this Article” feature allows readers to quickly send an article they find interesting to their entire networks, because all the content is openly accessible.

Articles in the Synthetic Biology Collection are presented in order of publication date and new articles will be added as they are published. PLOS ONE welcomes submissions in this field.

Collection Citation: Synthetic Biology (2012) PLOS Collections:http://www.ploscollections.org/syntheticbiology

Image Credit: Ivan Morozov (Virginia Bioinformatics Institute)

SOURCE

http://www.ploscollections.org/article/browseIssue.action?issue=info:doi/10.1371/issue.pcol.v02.i18

PLOS ONE Launches Synthetic Biology Collection

By Rachel Bernstein
Posted: August 15, 2012

Today PLOS ONE is happy to announce the launch of the Synthetic Biology Collection, including over 50 papers published in the last six years that illustrate the many facets of this dynamically evolving research area.

Synthetic biology is an innovative emerging field that exists at the intersection of many traditional disciplines, including biology, chemistry, and engineering, with aims to create biological systems that can be programmed to do useful things like produce drugs or biofuels, among other applications. Despite its potential, the heavily interdisciplinary nature of the research can make it difficult to publish in traditional discipline-specific journals.

However, PLOS ONE’s broad scope allows for the publication of work crossing many traditional research boundaries, making it an ideal venue for many different types of synthetic biology research. For example, the papers in the collection cover topics including DNA synthesis and assembly, standardized biological “parts” akin to interchangeable mechanical parts, protein engineering, and complex network and pathway analysis and modeling, as described in theCollection Overview written by collection editors Jean Peccoud of Virginia Tech and Mark Isalan of the Centre for Genomic Regulation.

The Collection has roots in PLOS ONE’s very first issue, which included two publications from the field. Since then, the number of synthetic biology articles published in the journal has grown steadily. The collection launched today highlights selected synthetic biology articles published in PLOS ONE since 2006, and it is intended to be a growing resource that will be updated regularly with new papers as the field continues to grow and develop.

Collection Citation: Synthetic Biology (2012) PLOS Collections:http://www.ploscollections.org/syntheticbiology

Image Credit: Ivan Morozov (Virginia Bioinformatics Institute)

SOURCE

http://blogs.plos.org/everyone/2012/08/15/plos-one-launches-synthetic-biology-collection/

The PLOS ONE Synthetic Biology Collection: Six Years and Counting

Jean Peccoud, Mark Isalan

PLoS ONE:
Published 15 Aug 2012 | info:doi/10.1371/journal.pone.0043231

The PLOS ONE Synthetic Biology Collection: Six Years and Counting 

Jean Peccoud1,2*, Mark Isalan3

1 Virginia Bioinformatics Institute, Virginia Tech, Blacksburg, Virginia, United States of America, 2 Center for Systems Biology of Engineered Tissues, Institute for Critical Technologies and Applied Science, Virginia Tech, Blacksburg, Virginia, United States of America, 3 EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation (CRG) and UPF, Barcelona, Spain

Abstract 

Since it was launched in 2006, PLOS ONE has published over fifty articles illustrating the many facets of the emerging field of synthetic biology. This article reviews these publications by organizing them into broad categories focused on DNA synthesis and assembly techniques, the development of libraries of biological parts, the use of synthetic biology in protein engineering applications, and the engineering of gene regulatory networks and metabolic pathways. Finally, we review articles that describe enabling technologies such as software and modeling, along with new instrumentation. In order to increase the visibility of this body of work, the papers have been assembled into the PLOS ONE Synthetic Biology Collection (www.ploscollections.org/synbio). Many of the innovative features of the PLOS ONE web site will help make this collection a resource that will support a lively dialogue between readers and authors of PLOS ONE synthetic biology papers. The content of the collection will be updated periodically by including relevant articles as they are published by the journal. Thus, we hope that this collection will continue to meet the publishing needs of the synthetic biology community.

Citation: Peccoud J, Isalan M (2012) The PLOS ONE Synthetic Biology Collection: Six Years and Counting. PLoS ONE 7(8): e43231. doi:10.1371/journal.pone.0043231

Editor: Wei Ning Chen, Nanyang Technological University, Singapore

 

Received: May 23, 2012; Accepted: July 16, 2012; Published: August 15, 2012

Copyright: © 2012 Peccoud, Isalan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: JP is supported by National Science Foundation Awards 0850100 and 0963988 and by grants R01-GM078989 and R01-GM095955 from the National Institutes of Health. MI is funded by FP7 ERC 201249 ZINC-HUBS, Ministerio de Ciencia e Innovacion grant MICINN BFU2010-17953 and the MEC-EMBL agreement. The funders had no role in the preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: peccoud@vt.edu

Introduction

Synthetic biology is an emerging transdisciplinary field at the intersection between many engineering and scientific disciplines such as biology, chemical engineering, chemistry, electrical engineering, or computer science. The scientific milestone that inspired the development of synthetic biology is often regarded as the description of two artificial gene networks in the same issue of Nature in 2000 [1][2]. However, the year 2004 marks the emergence of synthetic biology as a scientific community. This is the year of the first synthetic biology conference, the first iGEM competition –where students compete to build biological systems (http://igem.org/) ― and the creation of the synthetic biology page on Wikipedia. Two years later, the first issue of PLOS ONE included two synthetic biology articles [3][4], marking the beginning of a trend. Since then, PLOS ONE has published a large number of articles covering all aspects of the field. Synthetic biologists resolutely push the limits of their specialties in ways that few established journals have been able to appreciate. Since the result is often more “how to build something that works” rather than primary biological insight, the papers can be hard to place in classical journals. Many synthetic biology authors have benefited from the innovative PLOS ONE editorial policy to publish scientifically sound research, irrespective of its anticipated significance.

The purpose of this article is to introduce the PLOS ONE Synthetic Biology Collection (www.ploscollections.org/synbio/). The collection highlights selected synthetic biology articles published in PLOS ONE since 2006, putting them together in one place for easy perusal. The website is intended to be a growing resource that will be updated regularly.

We review the collection here by organizing it into some broad categories: DNA synthesis and assembly, Biological parts, Protein engineering, Networks and pathways, Synthetic life, Software and modeling, and Instruments. The classification is our own; since many synthetic biology papers cited in this review span more than one category, it was sometimes difficult to assign them to one category rather than another. Nonetheless, this structure should aid in navigating the 50+ papers currently included in the collection.

Summary of Papers Included in the Collection 

DNA Synthesis and Assembly

Synthetic biology projects often begin with the assembly of complicated, multi-component gene constructs. Therefore, both DNA assembly and cloning technologies are critical enablers of synthetic biology. Not surprisingly, many recent PLOS ONE papers propose methods to improve the efficiency of the fabrication step of synthetic biology projects. For example, Golden Gate Cloning [5] is a one-step DNA assembly protocol that can join at least nine distinct DNA fragments into one plasmid vector. The technique employs type IIs restriction enzymes that cut DNA at some distance from their cognate DNA-binding site, thus allowing flexibility and uniqueness in the compatible sticky ends that are generated. A related technique is GoldenBraid Assembly [6], that also uses type IIs restriction enzymes, but applies them iteratively to standardized DNA parts (see the ‘Biological parts’ section below). This allows the indefinite growth of reusable gene modules. Similarly, type IIs restriction enzymes have been used to make a hierarchical modular cloning system aimed at making eukaryotic multigene constructs [7].

‘One-pot’ assembly and cloning systems are being developed by many groups, and the ideal systems use as few standardized components as possible. Circular polymerase extension cloning (CPEC) fits into this category, using a single polymerase to assemble and clone multiple inserts with any vector, in a one-step in vitro reaction [8]. Alternatively, successive hybridization assembling (SHA) also employs a single reaction in vitro [9].

As well as cloning one desired multi-component construct, many projects require degenerate cloning or mutagenesis to make combinatorial libraries of gene variants. The OmniChange technique, which simultaneously saturates five independent codons, has therefore been developed to generate full-length gene libraries with 5 degenerate NNK-codons while avoiding PCR-amplification [10]. Large libraries of genetic sequences can be derived from oligonucleotides synthetized in a microarray, and later pooled in libraries from which more complex sequences can be derived [11]. By combining linear DNA amplification and PCR, DNA libraries with hundreds to thousands of members can be synthesized.

PCR methods themselves can have certain limitations, such as difficulties in amplifying GC-rich DNA targets. One study optimized polymerase chain assembly (PCA) and ligase chain reaction (LCR) methods for the construction of two GC-rich gene fragments implicated in tumorigenesis, IGF2R and BRAF [12]. They found that LCR was superior and benefited from the addition of DMSO and betaine.

The many synthesis and assembly methods presented in the collection can be combined to streamline the fabrication steps of synthetic biology projects, by producing collections of standardized biological parts. Standard parts are themselves a distinctive feature of synthetic biology, as reviewed below.

Biological Parts

The Registry of Standard Biological Parts (www.partsregistry.org), based on the original vision of Tom Knight, is providing a rich collection of components for synthetic biology projects. Several articles in the PLOS ONE collection reflect the importance of this resource. For example, a global analysis of the Registry clone collection [13] helped identify certain discrepancies between the sequences recorded in the database and the physical sequences of some clones in the collection. These results prompted a change in the quality control of the submissions to the Registry that has greatly improved the overall quality of the collection. Moreover, the analysis of parts usage patterns led to organizational guidelines that may help design and manage these new types of scientific resources. As most parts in the registry are for prokaryotes, a eukaryotic collection of 52 parts was developed and is available for distribution[14]. This includes multiple cloning sites (MCS), common protein tags, protein reporters and selection markers, amongst others. Furthermore, most of the parts were designed in a format to allow fusions that maintain the reading frame.

As well as standardized coding regions, synthetic biology projects require well-characterized promoters to achieve desired expression strengths. In one study, a single yeast promoter was mutated to make a fine-graded output range promoter library [15]. Transcription Activator-Like Orthogonal Repressors were then developed synthetically to control expression of these promoters in an orthogonal manner. Such orthogonality or ‘non-cross-reactivity’ is necessary for engineering larger synthetic gene circuits that do not interfere with the physiology of the biological chassis in which they operate. Mammalian synthetic promoters have also been developed by analyzing motifs found in highly active human promoters. Thus, by modulating the amount of sequences rich in GC and CpGs, custom designed promoters were obtained [16].

Finally, entirely de novo parts that are found nowhere in nature have been engineered to slot into biological systems. Using E. coli lacking conditionally essential genes, entirely new functional proteins were obtained from scaffolds of randomized 4-helix bundles, rescuing stalled growth [17]. Similarly, a synthetic ATP-binding protein, evolved entirely from non-natural sequences, was expressed in E. coli, altering the levels of intracellular ATP [18]. Protein engineering approaches are thus a potential source of many new parts, as well as forming a branch of synthetic biology in their own right.

Protein Engineering

Protein engineering can take many forms, from directed evolution methods to protein design. The PLOS ONE Synthetic Biology Collection includes a wide range of studies in this broad field.

Phage display is one of the classic tools of protein engineering, allowing combinatorial libraries of randomized proteins to be selected from the surface of bacteriophages. Phage display was used to generate a new class of binding proteins targeted to the pointed-end of actin [19]. These proteins, called synthetic antigen binders (sABs), were based on an antibody-like scaffold where sequence diversity is introduced into the binding loops using a new “reduced genetic code” phage display library.

An example of targeted protein design was the design of a dual reporter, Gemini [20]. Here, β-galactosidase (β-gal) α-fragment was fused to GFP, resulting in increased β-gal activity and some decrease in GFP sensitivity. GFP was also modified in a study where the ten proline residues of enhanced green fluorescent protein (EGFP) were replaced by (4R)- and (4S)-fluoroprolines (FPro) [21]. In this way, protein folding and stability could be tuned.

A promising advance in the field of engineering custom sequence-specific DNA-binding proteins is the use of Transcription Activator-Like (TAL) proteins. Modular TAL units specify A, C, G or T and can be concatenated to make long designer DNA-binding domains. Thus, Golden TAL Technology [22] has adapted Golden Gate Cloning [5] for engineering new TAL proteins. These were shown to function in human and plant cells and to target activation of both exogenous and endogenous genes, after fusion with a VP16 activation domain.

As well as single proteins, entire pathways can nowadays be engineered. Computational redesign was used to create new periplasmic binding proteins in plants, to act as biosensors in combination with a histidine kinase signaling cascade [23]. This resulted in transcription factor activation and ‘de-greening’ of plants in response to small-molecule stimuli. As can be seen from this example and the ones below, the move from single protein engineering to network engineering is one of the main driving forces in synthetic biology.

Networks and Pathways

One of the first, and now most-cited, synthetic biology papers in PLOS ONE was the study on fitness-induced attractor selection [3]. Here, a synthetic mutual inhibition gene network was built in E. coli, with two states, green (GFP) and red (RFP), that were mutually exclusive. By attaching a fitness pressure to one of the states (i.e. a gene required for growth in the absence of glutamine), the authors demonstrated that the cells switched stochastically into the fittest state, restoring growth. In other words, by changing to a glutamine-free medium, the red cells switched to green, even in the absence of formal signaling machinery. This work has important messages for potential new mechanisms in gene regulation, where underlying fitness pressures can ultimately determine how much a gene is expressed, simply according to need.

Other small bacterial networks have been built to include a heritable sequential memory switch, using the fim and hin inversion recombination systems [24], and an E. coli strain for use as a ‘chemical recording device’ [25]. In the latter, the authors created a synthetic chemically sensitive genetic toggle switch to activate appropriate fluorescent protein indicators (GFP, RFP) and along with a cell division inhibitor (minC). Moving to yeast, one example of network engineering was the reconstruction of a human p53-Mdm2 negative feedback module in S. cerevisiae [26]. In this example, many aspects of p53 regulation in mammals were maintained, such as Mdm2-dependent targeting of p53 for degradation, sumoylation at lysine 386 and further regulation of this process by p14ARF. In mammalian systems, a synthetic tetracycline regulator positive feedback loop was stably integrated and yielded a bimodal expression response because such cells can only be “OFF” or “ON” [27].

One unusual work in synthetic biology aimed to rewire and control cell shape in yeast, by changing the inputs into the α-factor pathway [28]. This pathway can give rise to multiple mating projections, upon prolonged activation. The authors tested genetic manipulations that ultimately gave rise to single or multiple projections, in the absence of the natural input, α-factor.

A group of papers in the collection explore ‘synthetic ecology’, where consortia of different cells interact to give patterns at a population level. For example, by engineering two strains of E. coli, one study was able to achieve synthetic biofilms with spatial self-organization [29]. The consortia achieved defined layered structures and had unexpected growth advantages. A second paper describes a systems composed of two quorum-sensing signal transduction circuits that allowed the authors to build a synthetic ecosystem where the population dynamics could be tuned by varying the environmental signals [30]. Third, quorum components were also used in a study which generated robust but unexpected oscillations in E. coli by building synthetic suicide circuits [31]. In fact, the quorum components proved to be unnecessary to achieve oscillations: there was a density-dependent plasmid amplification that gave rise to population-level negative feedback, ultimately resulting in the cycles. As in other areas of synthetic biology, the process of building systems often leads to surprises which can result in useful new engineering tools, or to a better understanding of the underlying biological processes [32].

Pathway engineering for the production of useful chemical or product synthesis is a major field within synthetic biology. For example, an engineered yeast that efficiently secretes penicillin was built by transplanting synthesis pathway components into a host that is more suited for pharmaceutical production [33]. Artemisinin derivatives are key components of malaria therapies and their synthesis is a high-profile goal of synthetic biology because extraction from slow-growing plants currently limits supply. Consequently, one study achieved high-level production of an artemisinin precursor in E. coli[34]. Another striking synthesis paper demonstrates a synthetic enzymatic pathway consisting of 13 enzymes for high-yield hydrogen production from starch and water [35]. Building such large systems is extremely challenging; as a result, these articles have received a lot of attention.

Synthetic Life

Synthetic life is among the most controversial of synthetic biology aims, and has received a lot of attention, even in the mainstream press. Public concerns of possible biological threats resulting from the misuse of these technologies prompted the development of new biosecurity policies [36].

One branch of this field is the de novo chemical synthesis and assembly of whole plasmids, viruses and genomes which are then transplanted into host cells. The pX1.0 plasmid is an example of a fully chemically-synthesized plasmid designed by calculating consensus sequences from 8 plasmids [37], while removing genes involved in antibiotic resistance and virulence. The plasmid not only replicated inE. coli, but could also self-transfer by conjugation into two other enterobacter species. A chemical synthesis approach was also used to construct whole genomes of bacteriophage G4 (around 10 kilobases in length), resulting in infectious viruses that could pass from one strain of E. coli to another[38].

One group has the ambitious long-term aim of building a synthetic chloroplast, and has begun by transplanting photosynthetic bacteria into eukaryotic cells to see whether they can achieve synthetic symbiosis [39]. Remarkably, the authors showed that some cyanobacteria were relatively harmless in zebrafish embryos, compared to E. coli. Furthermore, by engineering invasins into the cyanobacteria, they were able to invade and divide inside mammalian macrophages. Synthetic biology is only limited by our imagination, and one can speculate that entire free-living synthetic lifeforms could find their place in the collection in the not-too-distant future.

Software and Modeling

As the number of biological parts for synthetic biology increases, databases and design methods must evolve. For example, to help researchers search and retrieve biological parts, the Knowledgebase of Standard Biological Parts (SBPkb) is a Semantic Web resource for synthetic biology [40].

The collection also includes two articles presenting Computer Assisted Design software tools. Eugene is a human readable language to specify synthetic biological designs based on biological parts. It also provides a very expressive constraint system to drive the automatic creation of composite parts or devices from a collection of individual parts [41]. Alternatively, the Proto platform also provides a high-level biologically-oriented programming language [42]. Specifications are compiled from regulatory motifs, optimized, then converted into computational simulations for numerical verification.

Ultimately the design tools are only as good as the underlying mathematical models they rely on to make predictions of design behaviors. The collection includes a number of articles applying mathematical modeling approaches rooted in various engineering specialties to the design of synthetic genetic constructs.

Modeling gene networks is at the interface of systems and synthetic biology, and many PLOS ONE modeling papers aim to guide bioengineering projects. A recent example of adapting modeling for re-engineering properties into a system used a standardized synthetic yeast network from the In-vivo Reverse-engineering and Modeling Assessment (IRMA) [43]. Reverse engineering itself was used in a study which ultimately provided guidelines for chemotaxis pathway redesign [44]. Statecharts are used to describe dynamical systems, but have not been applied to gene networks. By doing so explicitly, one study was able to model network motifs and combine them in a complicated interlocked feed-forward loop network [45].

Two-component systems are common regulatory motifs in bacteria, and comprise a kinase that senses environmental signals together with a regulator that mediates the cell response. A recent study asked the question, “what happens if you add a third component that interacts with either of the other two?”[46]. Estimating the parameter space associated with a particular function is very valuable for guiding synthetic engineering approaches, as is determining whether a function is theoretically possible at all. For example, using a geometric argument, it was shown that, surprisingly, even monomer regulators can achieve bistability. This demonstrates the possibility of switch-like behavior in feedback autoloops without resorting to multimer regulators [47].

thumbnailFigure 1. Historical distribution of synthetic biology articles published by PLOS ONE.

This figure reports the number of articles in the collection published between 2006 and 2011. It shows a rapid growth of synthetic biology that reflects the growth of the journal and the increased familiarity of synthetic biologists with PLOS ONE.

doi:10.1371/journal.pone.0043231.g001

By combining experiments and computation, one study was able to derive design algorithms for altering synonymous codons in proteins, resulting in drastic expression differences of the same protein sequence[48]. For example, with DNA polymerase and single chain antibodies, expression could be predictably tuned to obtain concentrations ranging from undetectable to 30% of cellular protein. Importantly, using partial least squares regression, the authors noticed that favorable codons were predominantly those read by tRNAs that are most highly charged during amino acid starvation, not codons that are most abundant in highly expressed E. coli proteins. This is an important discovery for building genetic constructs that express appropriately inside the target cells.

Computation is a key function of biological networks and several studies in the collection present schemes to achieve this. The first is implemented at the level of chemical reactions and describes functions such as an inverter, an incrementer, a decrementer, a copier, a comparator, a multiplier, an exponentiator, a raise-to-a-power operation, and a logarithm in base two [49]. A key simplification is that the scheme uses only two reaction rates (“fast” and “slow”). A second study models a synthetic gene network to perform frequency multiplication [50]. Both of these studies assume deterministic relationships between input and outputs. Recently, the deterministic assumption has been challenged by experimental and theoretical works analyzing the importance of noise in the dynamics of gene networks [51]. This trend is illustrated in the collection by an article demonstrating that reliable timing of decision-making processes (choosing between multistable states) can be accomplished for large enough population sizes, as long as cells are globally coupled by chemical means [52]. Modeling can often reveal subtle non-intuitive designs, and, as a means of guiding synthetic biology, is likely to become an even larger field in the future.

thumbnailFigure 2. Relationships between article-level metrics.

For articles published between 2006 and 2009, there is a positive correlation between the number of times an article is cited in the scientific literature and the number of times it is viewed (A). For articles published between 2010 and 2012, there is a positive relationship between the number of views and the number of citations in the Mendeley social network (B). Metrics, such as number of views and citations in social media, give readers and authors an estimate of the scientific impact of individual articles well before they receive citations in scientific literature.

doi:10.1371/journal.pone.0043231.g002

Instruments

Nowadays, new technology and machinery is an important driving force for both primary biological discovery and for synthetic biology. A neat example is provided by the use of inkjet printer technology to provide low-cost high-resolution tools; a bacterial piezoelectric inkjet printer was designed to print out different strains of bacteria or chemicals in small droplets onto a flat surface at high resolution [53]. Another group used an inkjet for continuous dosing of diffusible regulators to a gel culture of E. coli, allowing 2D spatiotemporal regulation [54]. Precise spatiotemporal control of cells can also be achieved with microfluidics, and a recent report grew dividing yeast cells in a remarkable planar array [55]. Transient pulses of gene expression could be triggered by briefly inducing the GAL1 or MET3 promoters, resulting in coherent induction of cell division across the cell cluster. Other novel culture systems presented in the collection include the development of a 3-D cell culture system using a designer peptide nanofiber scaffold that self-assembled [4]. The peptide could be linked to functional motifs for cell adhesion, differentiation, and bone marrow homing for use with mouse adult neural stem cells.

The Synthetic Biology Collection: A Dynamic Community Resource Top

It is remarkable that the collection includes several articles originating from engineers and computer scientists who traditionally publish their work in conference proceedings rather than the journals available to life-scientists. PLOS ONE’s indifference to subject matter made it possible to publish an unprecedented body of articles that reflects the multi-faceted nature of synthetic biology. No less remarkable is the observation that PLOS ONE published several articles originating from iGEM projects[13][41][56].

Since 2006, the number of synthetic biology articles published by the journal has been growing steadily (Figure 1). This evolution is consistent with the social trends in synthetic biology that have been mapped in an interesting bibliometric analysis included in the collection [57]. This is an indication that the synthetic biology community is becoming more aware of the services provided by the journal. Looking forward, the collection will make it easier to identify synthetic biology articles among the quickly growing volume of articles published by the journal each day. The content of the collection will be updated periodically as new synthetic biology articles are published by the journal.

Although Journal Impact Factors are a widely-discredited form of evaluating the quality of individual papers, all too often they are still used. Thus, it is imperative to find a better alternative. One of the most exciting features of the PLOS ONE web site is the Metrics tab, displaying article-based metrics that can be used to assess the impact of individual articles. These metrics naturally include traditional indicators, such as the number of citations. The two articles of the collection published in 2006 have been cited 70 and 84 times so far. Almost all the articles published in 2007 and 2008 have received more than 10 citations. The lag between the publication of an article and its citation by others is well known. Fortunately, the Metrics tab also includes more innovative indicators that give the authors and readers alike a real-time estimate of the ‘impact’ of an article. The number of times an article is viewed is an important indicator. Since PLOS ONE is an online journal, all readers view articles online in one way or another. As a result, we hypothesized that the number of times an article was viewed should be a good predictor of the number of citations it will receive. Using data reported in Table S1, we analyzed the relationship between views and citation numbers for articles included in the collection that were published between 2006 and 2009. Figure 2 shows that there is a positive correlation between the two metrics. That relationship does not hold when including more recent articles because of a difference in timing between viewing and citing activities. Articles typically receive a substantial number of views in the first few months after publication, but it takes a few years before they are cited. The 20 articles of the collection published in 2011 have recorded a lot of views, but have not had the time to be cited in the literature yet.

A non-conventional form of citations displayed in the Metrics tab is the number of times an article is bookmarked in social media. We have reported the Mendeley (www.mendeley.com) data in Table S1.Figure 2 shows that there is a positive relationship between the number of views and the number of times articles are bookmarked in this network, at least for the most recent articles of the collection. Older articles are under-represented in Mendeley because this network was not available at the time these articles were published. It will be interesting to see if citations of the collection articles in social media will be a better predictor of citations in the scientific literature than the number of views.

One overarching theme of synthetic biology is standardization [58][59], which can only be achieved through concerted efforts by members of the community. The field has therefore been deeply influenced by the development of resources such as the Registry of Standard Biological Parts (www.partsregistry.org ). More recently, the development of SBOL, the Open Language for Synthetic Biology (www.sbolstandard.org) illustrates the need to agree on data formats suitable to the development of software tool chains necessary to support experimental efforts. Each article published in PLOS ONE can be the start of a lively conversation. The journal web site provides authors and readers alike with a detailed vision of community connections. The “Share this article” feature allows readers to quickly send an article they find interesting to their networks. The comments tab of the articles provides the community with means to engage in a dialogue focused on specific articles [5][35][48][55]. This feature can also be used by authors to provide updated information about the work presented in the article [13].

When working at its best, science should be an active conversation that keeps refining ideas. We believe that PLOS ONE provides the ideal venue to achieve this, and we hope that the collection will inspire further progress in synthetic biology. Ultimately, we hope that having a clear repository in PLOS ONE should further increase its attractiveness as a home for publishing synthetic biology.

Table S1.

Article-level statistics for the Synthetic Biology Collection.

(XLSX)

Author Contributions

Wrote the paper: JP MI.

References Top

  1. Elowitz MB, Leibler S (2000) A synthetic oscillatory network of transcriptional regulators. Nature 403: 335–338. FIND THIS ARTICLE ONLINE
  2. Gardner TS, Cantor CR, Collins JJ (2000) Construction of a genetic toggle switch in Escherichia coli. Nature 403: 339–342. FIND THIS ARTICLE ONLINE
  3. Kashiwagi A, Urabe I, Kaneko K, Yomo T (2006) Adaptive Response of a Gene Network to Environmental Changes by Fitness-Induced Attractor Selection. PLoS ONE 1: e49. FIND THIS ARTICLE ONLINE
  4. Gelain F, Bottai D, Vescovi A, Zhang S (2006) Designer Self-Assembling Peptide Nanofiber Scaffolds for Adult Mouse Neural Stem Cell 3-Dimensional Cultures. PLoS ONE 1: e119. FIND THIS ARTICLE ONLINE
  5. Engler C, Gruetzner R, Kandzia R, Marillonnet S (2009) Golden gate shuffling: a one-pot DNA shuffling method based on type IIs restriction enzymes. PLoS One 4: e5553. FIND THIS ARTICLE ONLINE
  6. Sarrion-Perdigones A, Falconi E, Zandalinas S, Juárez P, Fernández-del-Carmen A, et al. (2011) GoldenBraid: An Iterative Cloning System for Standardized Assembly of Reusable Genetic Modules. PLoS ONE 6: e21622. FIND THIS ARTICLE ONLINE
  7. Weber E, Engler C, Gruetzner R, Werner S, Marillonnet S (2011) A Modular Cloning System for Standardized Assembly of Multigene Constructs. PLoS ONE 6: e16765. FIND THIS ARTICLE ONLINE
  8. Quan J, Tian J (2009) Circular Polymerase Extension Cloning of Complex Gene Libraries and Pathways. PLoS ONE 4: e6441. FIND THIS ARTICLE ONLINE
  9. Jiang X, Yang J, Zhang H, Zou H, Wang C, et al. (2012) In Vitro Assembly of Multiple DNA Fragments Using Successive Hybridization. PLoS ONE 7: e30267. FIND THIS ARTICLE ONLINE
  10. Dennig A, Shivange A, Marienhagen J, Schwaneberg U (2011) OmniChange: The Sequence Independent Method for Simultaneous Site-Saturation of Five Codons. PLoS ONE 6: e26222.FIND THIS ARTICLE ONLINE
  11. Svensen N, Díaz-Mochón JJ, Bradley M (2011) Microarray generation of thousand-member oligonucleotide libraries. PLoS ONE 6: e24906. FIND THIS ARTICLE ONLINE
  12. Jensen M, Fukushima M, Davis R (2010) DMSO and Betaine Greatly Improve Amplification of GC-Rich Constructs in De Novo Synthesis. PLoS ONE 5: e11024. FIND THIS ARTICLE ONLINE
  13. Peccoud J, Blauvelt MF, Cai Y, Cooper KL, Crasta O, et al. (2008) Targeted Development of Registries of Biological Parts. PLoS ONE 3: e2671. FIND THIS ARTICLE ONLINE
  14. Constante M, Grünberg R, Isalan M (2011) A Biobrick Library for Cloning Custom Eukaryotic Plasmids. PLoS ONE 6: e23685. FIND THIS ARTICLE ONLINE
  15. Blount BA, Weenink T, Vasylechko S, Ellis T (2012) Rational Diversification of a Promoter Providing Fine-Tuned Expression and Orthogonal Regulation for Synthetic Biology. PLoS ONE 7: e33279.FIND THIS ARTICLE ONLINE
  16. Grabherr M, Pontiller J, Mauceli E, Ernst W, Baumann M, et al. (2011) Exploiting Nucleotide Composition to Engineer Promoters. PLoS ONE 6: e20136. FIND THIS ARTICLE ONLINE
  17. Fisher M, McKinley K, Bradley L, Viola S, Hecht M (2011) De Novo Designed Proteins from a Library of Artificial Sequences Function in Escherichia Coli and Enable Cell Growth. PLoS ONE 6: e15364.FIND THIS ARTICLE ONLINE
  18. Stomel J, Wilson J, León M, Stafford P, Chaput J (2009) A Man-Made ATP-Binding Protein Evolved Independent of Nature Causes Abnormal Growth in Bacterial Cells. PLoS ONE 4: e7385. FIND THIS ARTICLE ONLINE
  19. Brawley C, Uysal S, Kossiakoff A, Rock R (2010) Characterization of Engineered Actin Binding Proteins That Control Filament Assembly and Structure. PLoS ONE 5: e13960. FIND THIS ARTICLE ONLINE
  20. Martin L, Che A, Endy D (2009) Gemini, a bifunctional enzymatic and fluorescent reporter of gene expression. PLoS One 4: e7569. FIND THIS ARTICLE ONLINE
  21. Steiner T, Hess P, Bae JH, Wiltschi B, Moroder L, et al. (2008) Synthetic Biology of Proteins: Tuning GFPs Folding and Stability with Fluoroproline. PLoS ONE 3: e1680. FIND THIS ARTICLE ONLINE
  22. Weber E, Gruetzner R, Werner S, Engler C, Marillonnet S (2011) Assembly of Designer TAL Effectors by Golden Gate Cloning. PLoS ONE 6: e19722. FIND THIS ARTICLE ONLINE
  23. Antunes M, Morey K, Smith J, Albrecht K, Bowen T, et al. (2011) Programmable Ligand Detection System in Plants through a Synthetic Signal Transduction Pathway. PLoS ONE 6: e16292. FIND THIS ARTICLE ONLINE
  24. Ham T, Lee S, Keasling J, Arkin A (2008) Design and Construction of a Double Inversion Recombination Switch for Heritable Sequential Genetic Memory. PLoS ONE 3: e2815. FIND THIS ARTICLE ONLINE
  25. Bhomkar P, Materi W, Wishart D (2011) The Bacterial Nanorecorder: Engineering E. coli to Function as a Chemical Recording Device. PLoS ONE 6: e27559. FIND THIS ARTICLE ONLINE
  26. Di Ventura B, Funaya C, Antony C, Knop M, Serrano L (2008) Reconstitution of Mdm2-Dependent Post-Translational Modifications of p53 in Yeast. PLoS ONE 3: e1507. FIND THIS ARTICLE ONLINE
  27. May T, Eccleston L, Herrmann S, Hauser H, Goncalves J, et al. (2008) Bimodal and Hysteretic Expression in Mammalian Cells from a Synthetic Gene Circuit. PLoS ONE 3: e2372. FIND THIS ARTICLE ONLINE
  28. Tanaka H, Yi T-M (2009) Synthetic Morphology Using Alternative Inputs. PLoS ONE 4: e6946.FIND THIS ARTICLE ONLINE
  29. Brenner K, Arnold F (2011) Self-Organization, Layered Structure, and Aggregation Enhance Persistence of a Synthetic Biofilm Consortium. PLoS ONE 6: e16791. FIND THIS ARTICLE ONLINE
  30. Hu B, Du J, Zou R-y, Yuan Y-j (2010) An Environment-Sensitive Synthetic Microbial Ecosystem. PLoS ONE 5: e10619. FIND THIS ARTICLE ONLINE
  31. Marguet P, Tanouchi Y, Spitz E, Smith C, You L (2010) Oscillations by Minimal Bacterial Suicide Circuits Reveal Hidden Facets of Host-Circuit Physiology. PLoS ONE 5: e11909. FIND THIS ARTICLE ONLINE
  32. Elowitz M, Lim WA (2010) Build life to understand it. Nature 468: 889–890. FIND THIS ARTICLE ONLINE
  33. Gidijala L, Kiel J, Douma R, Seifar R, van Gulik W, et al. (2009) An Engineered Yeast Efficiently Secreting Penicillin. PLoS ONE 4: e8317. FIND THIS ARTICLE ONLINE
  34. Tsuruta H, Paddon C, Eng D, Lenihan J, Horning T, et al. (2009) High-Level Production of Amorpha-4,11-Diene, a Precursor of the Antimalarial Agent Artemisinin, in Escherichia coli. PLoS ONE 4: e4489. FIND THIS ARTICLE ONLINE
  35. Zhang P, Evans B, Mielenz J, Hopkins R, Adams M (2007) High-Yield Hydrogen Production from Starch and Water by a Synthetic Enzymatic Pathway. PLoS ONE 2: e456. FIND THIS ARTICLE ONLINE
  36. Adam L, Kozar M, Letort G, Mirat O, Srivastava A, et al. (2011) Strengths and limitations of the federal guidance on synthetic DNA. Nat Biotechnol 29: 208–210. FIND THIS ARTICLE ONLINE
  37. Hansen L, Bentzon-Tilia M, Bentzon-Tilia S, Norman A, Rafty L, et al. (2011) Design and Synthesis of a Quintessential Self-Transmissible IncX1 Plasmid, pX1.0. PLoS ONE 6: e19912. FIND THIS ARTICLE ONLINE
  38. Yang R, Han Y, Ye Y, Liu Y, Jiang Z, et al. (2011) Chemical Synthesis of Bacteriophage G4. PLoS ONE 6: e27062. FIND THIS ARTICLE ONLINE
  39. Agapakis C, Niederholtmeyer H, Noche R, Lieberman T, Megason S, et al. (2011) Towards a Synthetic Chloroplast. PLoS ONE 6: e18877. FIND THIS ARTICLE ONLINE
  40. Galdzicki M, Rodriguez C, Chandran D, Sauro H, Gennari J (2011) Standard Biological Parts Knowledgebase. PLoS ONE 6: e17005. FIND THIS ARTICLE ONLINE
  41. Bilitchenko L, Liu A, Cheung S, Weeding E, Xia B, et al. (2011) Eugene – A Domain Specific Language for Specifying and Constraining Synthetic Biological Parts, Devices, and Systems. PLoS ONE 6: e18882. FIND THIS ARTICLE ONLINE
  42. Beal J, Lu T, Weiss R (2011) Automatic Compilation from High-Level Biologically-Oriented Programming Language to Genetic Regulatory Networks. PLoS ONE 6: e22490. FIND THIS ARTICLE ONLINE
  43. Marucci L, Barton D, Cantone I, Ricci M, Cosma M, et al. (2009) How to Turn a Genetic Circuit into a Synthetic Tunable Oscillator, or a Bistable Switch. PLoS ONE 4: e8083. FIND THIS ARTICLE ONLINE
  44. Luo J, Wang J, Ma T, Sun Z (2010) Reverse Engineering of Bacterial Chemotaxis Pathway via Frequency Domain Analysis. PLoS ONE 5: e9182. FIND THIS ARTICLE ONLINE
  45. Shin Y-J, Nourani M (2010) Statecharts for Gene Network Modeling. PLoS ONE 5: e9376. FIND THIS ARTICLE ONLINE
  46. Salvado B, Vilaprinyo E, Karathia H, Sorribas A, Alves R (2012) Two Component Systems: Physiological Effect of a Third Component. PLoS ONE 7: e31095. FIND THIS ARTICLE ONLINE
  47. Widder S, Macía J, Solé R (2009) Monomeric Bistability and the Role of Autoloops in Gene Regulation. PLoS ONE 4: e5399. FIND THIS ARTICLE ONLINE
  48. Welch M, Govindarajan S, Ness J, Villalobos A, Gurney A, et al. (2009) Design Parameters to Control Synthetic Gene Expression in Escherichia coli. PLoS ONE 4: e7002. FIND THIS ARTICLE ONLINE
  49. Senum P, Riedel M (2011) Rate-Independent Constructs for Chemical Computation. PLoS ONE 6: e21414. FIND THIS ARTICLE ONLINE
  50. Purcell O, di Bernardo M, Grierson C, Savery N (2011) A Multi-Functional Synthetic Gene Network: A Frequency Multiplier, Oscillator and Switch. PLoS ONE 6: e16140. FIND THIS ARTICLE ONLINE
  51. Balazsi G, van Oudenaarden A, Collins JJ (2011) Cellular decision making and biological noise: from microbes to mammals. Cell 144: 910–925. FIND THIS ARTICLE ONLINE
  52. Koseska A, Zaikin A, Kurths J, García-Ojalvo J (2009) Timing Cellular Decision Making Under Noise via Cell–Cell Communication. PLoS ONE 4: e4872. FIND THIS ARTICLE ONLINE
  53. Merrin J, Leibler S, Chuang JS (2007) Printing multistrain bacterial patterns with a piezoelectric inkjet printer. PLoS ONE 2: e663. FIND THIS ARTICLE ONLINE
  54. Cohen D, Morfino R, Maharbiz M (2009) A Modified Consumer Inkjet for Spatiotemporal Control of Gene Expression. PLoS ONE 4: e7086. FIND THIS ARTICLE ONLINE
  55. Charvin G, Cross FR, Siggia ED (2008) A microfluidic device for temporally controlled gene expression and long-term fluorescent imaging in unperturbed dividing yeast cells. PLoS One 3: e1468. FIND THIS ARTICLE ONLINE
  56. Hesselman MC, Odoni DI, Ryback BM, de Groot S, van Heck RG, et al. (2012) A multi-platform flow device for microbial (co-) cultivation and microscopic analysis. PLoS One 7: e36982. FIND THIS ARTICLE ONLINE
  57. Oldham P, Hall S, Burton G (2012) Synthetic biology: mapping the scientific landscape. PLoS One 7: e34368. FIND THIS ARTICLE ONLINE
  58. Endy D (2005) Foundations for engineering biology. Nature 438: 449–453. FIND THIS ARTICLE ONLINE
  59. Canton B, Labno A, Endy D (2008) Refinement and standardization of synthetic biological parts and devices. Nat Biotechnol 26: 787–793. FIND THIS ARTICLE ONLINE
SOURCE

Research Articles

A Multi-Platform Flow Device for Microbial (Co-) Cultivation and Microscopic Analysis

Matthijn C. Hesselman, Dorett I. Odoni, Brendan M. Ryback, Suzette de Groot, Ruben G. A. van Heck, Jaap Keijsers, Pim Kolkman, David Nieuwenhuijse, Youri M. van Nuland, Erik Sebus, Rob Spee, Hugo de Vries, Marten T. Wapenaar, Colin J. Ingham, Karin Schroën, Vítor A. P. Martins dos Santos, Sebastiaan K. Spaans, Floor Hugenholtz, Mark W. J. van Passel

PLoS ONE:
Published 14 May 2012 | info:doi/10.1371/journal.pone.0036982

Synthetic Biology: Mapping the Scientific Landscape

Paul Oldham, Stephen Hall, Geoff Burton

PLoS ONE:
Published 23 Apr 2012 | info:doi/10.1371/journal.pone.0034368

Rational Diversification of a Promoter Providing Fine-Tuned Expression and Orthogonal Regulation for Synthetic Biology

Benjamin A. Blount, Tim Weenink, Serge Vasylechko, Tom Ellis

PLoS ONE:
Published 19 Mar 2012 | info:doi/10.1371/journal.pone.0033279

Two Component Systems: Physiological Effect of a Third Component

Baldiri Salvado, Ester Vilaprinyo, Hiren Karathia, Albert Sorribas, Rui Alves

PLoS ONE:
Published 17 Feb 2012 | info:doi/10.1371/journal.pone.0031095

In Vitro Assembly of Multiple DNA Fragments Using Successive Hybridization

Xinglin Jiang, Jianming Yang, Haibo Zhang, Huibin Zou, Cong Wang, Mo Xian

PLoS ONE:
Published 26 Jan 2012 | info:doi/10.1371/journal.pone.0030267

The Bacterial Nanorecorder: Engineering E. coli to Function as a Chemical Recording Device

Prasanna Bhomkar, Wayne Materi, David S. Wishart

PLoS ONE:
Published 23 Nov 2011 | info:doi/10.1371/journal.pone.0027559

Chemical Synthesis of Bacteriophage G4

Ruilin Yang, Yonghua Han, Yiwang Ye, Yuchen Liu, Zhimao Jiang, Yaoting Gui, Zhiming Cai

PLoS ONE:
Published 16 Nov 2011 | info:doi/10.1371/journal.pone.0027062

OmniChange: The Sequence Independent Method for Simultaneous Site-Saturation of Five Codons

Alexander Dennig, Amol V. Shivange, Jan Marienhagen, Ulrich Schwaneberg

PLoS ONE:
Published 19 Oct 2011 | info:doi/10.1371/journal.pone.0026222

Microarray Generation of Thousand-Member Oligonucleotide Libraries

Nina Svensen, Juan José Díaz-Mochón, Mark Bradley

PLoS ONE:
Published 23 Sep 2011 | info:doi/10.1371/journal.pone.0024906

A Biobrick Library for Cloning Custom Eukaryotic Plasmids

Marco Constante, Raik Grünberg, Mark Isalan

PLoS ONE:
Published 25 Aug 2011 | info:doi/10.1371/journal.pone.0023685

Automatic Compilation from High-Level Biologically-Oriented Programming Language to Genetic Regulatory Networks

Jacob Beal, Ting Lu, Ron Weiss

PLoS ONE:
Published 05 Aug 2011 | info:doi/10.1371/journal.pone.0022490

GoldenBraid: An Iterative Cloning System for Standardized Assembly of Reusable Genetic Modules

Alejandro Sarrion-Perdigones, Erica Elvira Falconi, Sara I. Zandalinas, Paloma Juárez, Asun Fernández-del-Carmen, Antonio Granell, Diego Orzaez

PLoS ONE:
Published 07 Jul 2011 | info:doi/10.1371/journal.pone.0021622

Rate-Independent Constructs for Chemical Computation

Phillip Senum, Marc Riedel

PLoS ONE:
Published 30 Jun 2011 | info:doi/10.1371/journal.pone.0021414

Assembly of Designer TAL Effectors by Golden Gate Cloning

Ernst Weber, Ramona Gruetzner, Stefan Werner, Carola Engler, Sylvestre Marillonnet

PLoS ONE:
Published 19 May 2011 | info:doi/10.1371/journal.pone.0019722

Design and Synthesis of a Quintessential Self-Transmissible IncX1 Plasmid, pX1.0

Lars H. Hansen, Mikkel Bentzon-Tilia, Sara Bentzon-Tilia, Anders Norman, Louise Rafty, Søren J. Sørensen

PLoS ONE:
Published 18 May 2011 | info:doi/10.1371/journal.pone.0019912

Exploiting Nucleotide Composition to Engineer Promoters

Manfred G. Grabherr, Jens Pontiller, Evan Mauceli, Wolfgang Ernst, Martina Baumann, Tara Biagi, Ross Swofford, Pamela Russell, Michael C. Zody, Federica Di Palma, Kerstin Lindblad-Toh, Reingard M. Grabherr

PLoS ONE:
Published 18 May 2011 | info:doi/10.1371/journal.pone.0020136

Eugene – A Domain Specific Language for Specifying and Constraining Synthetic Biological Parts, Devices, and Systems

Lesia Bilitchenko, Adam Liu, Sherine Cheung, Emma Weeding, Bing Xia, Mariana Leguia, J. Christopher Anderson, Douglas Densmore

PLoS ONE:
Published 29 Apr 2011 | info:doi/10.1371/journal.pone.0018882

Towards a Synthetic Chloroplast

Christina M. Agapakis, Henrike Niederholtmeyer, Ramil R. Noche, Tami D. Lieberman, Sean G. Megason, Jeffrey C. Way, Pamela A. Silver

PLoS ONE:
Published 20 Apr 2011 | info:doi/10.1371/journal.pone.0018877

Standard Biological Parts Knowledgebase

Michal Galdzicki, Cesar Rodriguez, Deepak Chandran, Herbert M. Sauro, John H. Gennari

PLoS ONE:
Published 24 Feb 2011 | info:doi/10.1371/journal.pone.0017005

A Modular Cloning System for Standardized Assembly of Multigene Constructs

Ernst Weber, Carola Engler, Ramona Gruetzner, Stefan Werner, Sylvestre Marillonnet

PLoS ONE:
Published 18 Feb 2011 | info:doi/10.1371/journal.pone.0016765

A Multi-Functional Synthetic Gene Network: A Frequency Multiplier, Oscillator and Switch

Oliver Purcell, Mario di Bernardo, Claire S. Grierson, Nigel J. Savery

PLoS ONE:
Published 17 Feb 2011 | info:doi/10.1371/journal.pone.0016140

Self-Organization, Layered Structure, and Aggregation Enhance Persistence of a Synthetic Biofilm Consortium

Katie Brenner, Frances H. Arnold

PLoS ONE:
Published 09 Feb 2011 | info:doi/10.1371/journal.pone.0016791

Programmable Ligand Detection System in Plants through a Synthetic Signal Transduction Pathway

Mauricio S. Antunes, Kevin J. Morey, J. Jeff Smith, Kirk D. Albrecht, Tessa A. Bowen, Jeffrey K. Zdunek, Jared F. Troupe, Matthew J. Cuneo, Colleen T. Webb, Homme W. Hellinga, June I. Medford

PLoS ONE:
Published 25 Jan 2011 | info:doi/10.1371/journal.pone.0016292

De Novo Designed Proteins from a Library of Artificial Sequences Function inEscherichia Coli and Enable Cell Growth

Michael A. Fisher, Kara L. McKinley, Luke H. Bradley, Sara R. Viola, Michael H. Hecht

PLoS ONE:
Published 04 Jan 2011 | info:doi/10.1371/journal.pone.0015364

Characterization of Engineered Actin Binding Proteins That Control Filament Assembly and Structure

Crista M. Brawley, Serdar Uysal, Anthony A. Kossiakoff, Ronald S. Rock

PLoS ONE:
Published 12 Nov 2010 | info:doi/10.1371/journal.pone.0013960

Oscillations by Minimal Bacterial Suicide Circuits Reveal Hidden Facets of Host-Circuit Physiology

Philippe Marguet, Yu Tanouchi, Eric Spitz, Cameron Smith, Lingchong You

PLoS ONE:
Published 30 Jul 2010 | info:doi/10.1371/journal.pone.0011909

DMSO and Betaine Greatly Improve Amplification of GC-Rich Constructs in De Novo Synthesis

Michael A. Jensen, Marilyn Fukushima, Ronald W. Davis

PLoS ONE:
Published 11 Jun 2010 | info:doi/10.1371/journal.pone.0011024

An Environment-Sensitive Synthetic Microbial Ecosystem

Bo Hu, Jin Du, Rui-yang Zou, Ying-jin Yuan

PLoS ONE:
Published 12 May 2010 | info:doi/10.1371/journal.pone.0010619

Reverse Engineering of Bacterial Chemotaxis Pathway via Frequency Domain Analysis

Junjie Luo, Jun Wang, Ting Martin Ma, Zhirong Sun

PLoS ONE:
Published 09 Mar 2010 | info:doi/10.1371/journal.pone.0009182

Statecharts for Gene Network Modeling

Yong-Jun Shin, Mehrdad Nourani

PLoS ONE:
Published 23 Feb 2010 | info:doi/10.1371/journal.pone.0009376

An Engineered Yeast Efficiently Secreting Penicillin

Loknath Gidijala, Jan A. K. W. Kiel, Rutger D. Douma, Reza M. Seifar, Walter M. van Gulik, Roel A. L. Bovenberg, Marten Veenhuis, Ida J. van der Klei

PLoS ONE:
Published 15 Dec 2009 | info:doi/10.1371/journal.pone.0008317

How to Turn a Genetic Circuit into a Synthetic Tunable Oscillator, or a Bistable Switch

Lucia Marucci, David A. W. Barton, Irene Cantone, Maria Aurelia Ricci, Maria Pia Cosma, Stefania Santini, Diego di Bernardo, Mario di Bernardo

PLoS ONE:
Published 07 Dec 2009 | info:doi/10.1371/journal.pone.0008083

Gemini, a Bifunctional Enzymatic and Fluorescent Reporter of Gene Expression

Lance Martin, Austin Che, Drew Endy

PLoS ONE:
Published 04 Nov 2009 | info:doi/10.1371/journal.pone.0007569

A Man-Made ATP-Binding Protein Evolved Independent of Nature Causes Abnormal Growth in Bacterial Cells

Joshua M. Stomel, James W. Wilson, Megan A. León, Phillip Stafford, John C. Chaput

PLoS ONE:
Published 08 Oct 2009 | info:doi/10.1371/journal.pone.0007385

A Modified Consumer Inkjet for Spatiotemporal Control of Gene Expression

Daniel J. Cohen, Roberto C. Morfino, Michel M. Maharbiz

PLoS ONE:
Published 18 Sep 2009 | info:doi/10.1371/journal.pone.0007086

Design Parameters to Control Synthetic Gene Expression in Escherichia coli

Mark Welch, Sridhar Govindarajan, Jon E. Ness, Alan Villalobos, Austin Gurney, Jeremy Minshull, Claes Gustafsson

PLoS ONE:
Published 14 Sep 2009 | info:doi/10.1371/journal.pone.0007002

Synthetic Morphology Using Alternative Inputs

Hiromasa Tanaka, Tau-Mu Yi

PLoS ONE:
Published 10 Sep 2009 | info:doi/10.1371/journal.pone.0006946

Circular Polymerase Extension Cloning of Complex Gene Libraries and Pathways

Jiayuan Quan, Jingdong Tian

PLoS ONE:
Published 30 Jul 2009 | info:doi/10.1371/journal.pone.0006441

Golden Gate Shuffling: A One-Pot DNA Shuffling Method Based on Type IIs Restriction Enzymes

Carola Engler, Ramona Gruetzner, Romy Kandzia, Sylvestre Marillonnet

PLoS ONE:
Published 14 May 2009 | info:doi/10.1371/journal.pone.0005553

Monomeric Bistability and the Role of Autoloops in Gene Regulation

Stefanie Widder, Javier Macía, Ricard Solé

PLoS ONE:
Published 30 Apr 2009 | info:doi/10.1371/journal.pone.0005399

Timing Cellular Decision Making Under Noise via Cell–Cell Communication

Aneta Koseska, Alexey Zaikin, Jürgen Kurths, Jordi García-Ojalvo

PLoS ONE:
Published 13 Mar 2009 | info:doi/10.1371/journal.pone.0004872

High-Level Production of Amorpha-4,11-Diene, a Precursor of the Antimalarial Agent Artemisinin, in Escherichia coli

Hiroko Tsuruta, Christopher J. Paddon, Diana Eng, Jacob R. Lenihan, Tizita Horning, Larry C. Anthony, Rika Regentin, Jay D. Keasling, Neil S. Renninger, Jack D. Newman

PLoS ONE:
Published 16 Feb 2009 | info:doi/10.1371/journal.pone.0004489

Design and Construction of a Double Inversion Recombination Switch for Heritable Sequential Genetic Memory

Timothy S. Ham, Sung K. Lee, Jay D. Keasling, Adam P. Arkin

PLoS ONE:
Published 30 Jul 2008 | info:doi/10.1371/journal.pone.0002815

Targeted Development of Registries of Biological Parts

Jean Peccoud, Megan F. Blauvelt, Yizhi Cai, Kristal L. Cooper, Oswald Crasta, Emily C. DeLalla, Clive Evans, Otto Folkerts, Blair M. Lyons, Shrinivasrao P. Mane, Rebecca Shelton, Matthew A. Sweede, Sally A. Waldon

PLoS ONE:
Published 16 Jul 2008 | info:doi/10.1371/journal.pone.0002671

Bimodal and Hysteretic Expression in Mammalian Cells from a Synthetic Gene Circuit

Tobias May, Lee Eccleston, Sabrina Herrmann, Hansjörg Hauser, Jorge Goncalves, Dagmar Wirth

PLoS ONE:
Published 04 Jun 2008 | info:doi/10.1371/journal.pone.0002372

Synthetic Biology of Proteins: Tuning GFPs Folding and Stability with Fluoroproline

Thomas Steiner, Petra Hess, Jae Hyun Bae, Birgit Wiltschi, Luis Moroder, Nediljko Budisa

PLoS ONE:
Published 27 Feb 2008 | info:doi/10.1371/journal.pone.0001680

Reconstitution of Mdm2-Dependent Post-Translational Modifications of p53 in Yeast

Barbara Di Ventura, Charlotta Funaya, Claude Antony, Michael Knop, Luis Serrano

PLoS ONE:
Published 30 Jan 2008 | info:doi/10.1371/journal.pone.0001507

A Microfluidic Device for Temporally Controlled Gene Expression and Long-Term Fluorescent Imaging in Unperturbed Dividing Yeast Cells

Gilles Charvin, Frederick R. Cross, Eric D. Siggia

PLoS ONE:
Published 23 Jan 2008 | info:doi/10.1371/journal.pone.0001468

Printing Multistrain Bacterial Patterns with a Piezoelectric Inkjet Printer

Jack Merrin, Stanislas Leibler, John S. Chuang

PLoS ONE:
Published 25 Jul 2007 | info:doi/10.1371/journal.pone.0000663

High-Yield Hydrogen Production from Starch and Water by a Synthetic Enzymatic Pathway

Y.-H. Percival Zhang, Barbara R. Evans, Jonathan R. Mielenz, Robert C. Hopkins, Michael W.W. Adams

PLoS ONE:
Published 23 May 2007 | info:doi/10.1371/journal.pone.0000456

Designer Self-Assembling Peptide Nanofiber Scaffolds for Adult Mouse Neural Stem Cell 3-Dimensional Cultures

Fabrizio Gelain, Daniele Bottai, Angleo Vescovi, Shuguang Zhang

PLoS ONE:
Published 27 Dec 2006 | info:doi/10.1371/journal.pone.0000119

Adaptive Response of a Gene Network to Environmental Changes by Fitness-Induced Attractor Selection

Akiko Kashiwagi, Itaru Urabe, Kunihiko Kaneko, Tetsuya Yomo

PLoS ONE:
Published 20 Dec 2006 | info:doi/10.1371/journal.pone.0000049

SOURCE

Read Full Post »

 

Tufts Health Plan to Cover Sequenom’s MaterniT21, Pathwork’s Tissue of Origin Tests

Reporter: Aviva Lev-Ari, PhD, RN

http://www.genomeweb.com/mdx/tufts-health-plan-cover-sequenoms-maternit21-pathworks-tissue-origin-tests

NEW YORK (GenomeWeb News) – Tufts Health Plan will begin covering Sequenom’s MaterniT21 Plus trisomy 21 test and Pathwork Diagnostics‘ Tissue of Origin test starting Oct. 1.

In an update to providers posted on its website, the health plan said that it may authorize coverage of the MaterniT21 test for patients who are plan members if they are at least 35 years old when they give birth; have a fetal aneuploidy screening test result including maternal serum screening and/or ultrasound evaluation that indicates the possibility of trisomy 21; or the plan member has a family history or prior pregnancy involving aneuploidy.

In a research note Oppenheimer analyst David Ferreiro said that Tufts Health Plan has approximately 1 million lives under coverage and a network of 90 hospitals and 25,000 healthcare providers.

“We view this decision as an incremental positive for [Sequenom] and as validation of the value proposition MaterniT21 presents to payors,” he said. “The adoption rate is encouraging and could positively impact payor decisions, further entrenching,” the company.

Two weeks ago, Sequenom said that in the second quarter revenues from its Sequenom Center for Molecular Medicine diagnostic services rose five-fold to $8.1 million driven by the MaterniT21 Plus test, which was launched in the fall. The test also detects for T18 and T13.

As adoption of the test continues to ramp at an increasing rate, the San Diego-based company increased its internal goal of billed MaterniT21 Plus tests for 2012 to 50,000 from an earlier goal of 40,000.

The company has stopped announcing coverage decisions by individual plans following an incident in the spring in which Coventry Health Care National Networkterminated a coverage decision for MaterniT21 Plus one week after Sequenom said that Coventy would cover the test. Sequenom said at the time that Coventry’s decision was without cause and was not a judgment on the company, Sequenom CMM, or its products.

In a statement today to GenomeWeb Daily News, a Sequenom spokesperson declined to disclose the terms of the contract with Tufts Health Plan. She said that Sequenom CMM has more than 26 million live under contract, and “we operate as an out-of-network laboratory where we are not yet contracted and bill payors accordingly.”

Tufts Health Plan also said that it will begin coverage of Pathwork Diagnostics’ Pathwork Tissue of Origin test, beginning on Oct. 1. The test is for the identification of challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers.

The plan said it may authorize coverage of the test if it is ordered by an oncologist and the plan member is diagnosed with metastatic cancer; the clinical evaluation has not identified the primary site of the cancer; the pathology report is submitted to Tufts Health Plan for review; and the pathology examination is unable to conclusively identify the primary site, or has identified two or more possible primary sites.

Use of the test to confirm a diagnosis will not be covered by the health plan.

 

 

Read Full Post »

« Newer Posts - Older Posts »